Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2BTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3MPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PPARGSLC6A2SLC6A3SLC6A4SMOTYK2pol
The experimentally established mechanism targets of Clentiazem. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1S known ✓ | Q13698 | 12/20 | 0.79 |
| ▸ | CACNA1F known ✓ | O60840 | 1/20 | 0.71 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.71 |
| ▸ | CACNA1D known ✓ | Q01668 | 1/20 | 0.71 |
| ▸ | CACNA1C known ✓ | Q13936 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.71 |
| ▸ | TSHR | P16473 | 2/20 | 0.71 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.71 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.71 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.71 |
| ▸ | HRH2 | P25021 | 1/20 | 0.71 |
| ▸ | SCN1A | P35498 | 1/20 | 0.71 |
| ▸ | SCN4A | P35499 | 1/20 | 0.71 |
| ▸ | HTT | P42858 | 1/20 | 0.71 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.71 |
| ▸ | PLAUR | Q03405 | 1/20 | 0.71 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.71 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clentiazem SCHEMBL7266652 | 1.00 | CACNA1S (0.79) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Clentiazem SCHEMBL387183 | 1.00 | CACNA1S (0.79) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Clentiazem SCHEMBL7267636 | 1.00 | CACNA1S (0.79) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Clentiazem SCHEMBL7266655 | 1.00 | CACNA1S (0.79) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Clentiazem SCHEMBL33910 | 0.95 | CACNA1S (0.86) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Clentiazem SCHEMBL7432489 | 0.95 | CACNA1S (0.86) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Clentiazem SCHEMBL33909 | 0.95 | CACNA1S (0.86) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Clentiazem SCHEMBL6616493 | 0.95 | CACNA1S (0.86) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Clentiazem SCHEMBL10830381 | 0.94 | CACNA1S (0.85) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Clentiazem SCHEMBL10830375 | 0.94 | CACNA1S (0.85) | CACNA1SCYP3A4TSHRABCB11LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 757 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260041336-A1 | PLATELET REACTIVITY EXPRESSION SCORE PREDICTS CARDIOVASCULAR RISK | NEW YORK UNIVERSITY (US) | 2026-02-12 | — | — | US | claimed |
| EP-2205639-B1 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | MERCK SHARP & DOHME (US) | 2015-12-23 | — | — | EP | claimed |
| US-20140161798-A1 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | MERCK SHARP & DOHME CORP. (US) | 2014-06-12 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| WO-2012054438-A1 | ANTI-PCSK9 | SCHERING CORPORATION (US) | 2012-04-26 | — | — | WO | claimed |
| US-20110033465-A1 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | SCHERING CORPORATION (US) | 2011-02-10 | — | — | US | claimed |
| EP-2205639-A2 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | SCHERING CORPORATION (US) | 2010-07-14 | — | — | EP | claimed |
| WO-2009055783-A2 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | SCHERING CORPORATION (US) | 2009-04-30 | — | — | WO | claimed |
| EP-1363668-B1 | COMBINATIONS OF BILE ACID SEQUESTRANT(S) AND STEROL ABSORPTION INHIBITOR(S) AND TREATMENTS FOR VASCULAR INDICATIONS | SCHERING CORP (US) | 2007-08-15 | — | — | EP | claimed |
| EP-1385548-B1 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | SCHERING CORP (US) | 2007-05-23 | — | — | EP | claimed |
| EP-1785144-A2 | Combinations of bile acids sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications | Shering Corporation (US) | 2007-05-16 | — | — | EP | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-1541175-A2 | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | Schering Corporation (US) | 2005-06-15 | — | — | EP | claimed |
| EP-1385548-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | Schering Corporation (US) | 2004-02-04 | — | — | EP | claimed |
| US-20030069221-A1 | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | SCHERING CORPORATION | 2003-04-10 | — | — | US | claimed |
| WO-2002058731-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | claimed |
| US-12605333-B2 | Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release | TRIS PHARMA, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20260096986-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A FLOATING INTERPENETRATING POLYMER NETWORK FORMING SYSTEM | TRIS PHARMA INC (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260041336-A1 | PLATELET REACTIVITY EXPRESSION SCORE PREDICTS CARDIOVASCULAR RISK | NEW YORK UNIVERSITY (US) | 2026-02-12 | — | — | US | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260034071-A1 | HIGH-PURITY PEG LIPIDS AND USES THEREOF | MODERNATX, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12514818-B2 | Pharmaceutical compositions comprising a floating interpenetrating polymer network forming system | TRIS PHARMA, INC. (US) | 2026-01-06 | — | — | US | disclosed |
| US-12465564-B2 | Oral and nasal compositions and methods of treatment | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250339367-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-12403090-B2 | Oral film compositions and dosage forms having precise active dissolution profiles | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250255780-A1 | SYSTEM AND METHOD FOR MAKING PERSONALIZED INDIVIDUAL UNIT DOSES CONTAINING PHARMACEUTICAL ACTIVES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-08-14 | — | — | US | disclosed |
| US-12383508-B2 | High-purity peg lipids and uses thereof | MODERNATX, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250171497-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | BAUSCH HEALTH IRELAND LIMITED (IE) | 2025-05-29 | — | — | US | disclosed |
| US-12310922-B2 | System and method for making personalized individual unit doses containing pharmaceutical actives | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20250152518-A1 | PEG LIPIDS AND USES THEREOF | MODERNATX, INC. (US) | 2025-05-15 | — | — | US | disclosed |
| US-12290597-B2 | Oral film compositions and dosage forms having precise active dissolution profiles | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| EP-4509118-A2 | HIGH-PURITY PEG LIPIDS AND USES THEREOF | ModernaTX, Inc. (US) | 2025-02-19 | — | — | EP | disclosed |
| US-20250049881-A1 | FORMULATIONS OF GUANYLATE CYCLSE C AGONISTS AND METHODS OF USE | JPMORGAN CHASE BANK, N.A. | 2025-02-13 | — | — | US | disclosed |
| US-12171723-B2 | System and method for making personalized individual unit doses containing pharmaceutical actives | AQUESTIVE THERAPEUTICS, INC. (US) | 2024-12-24 | — | — | US | disclosed |
| US-12151029-B2 | PEG lipids and uses thereof | MODERNATX, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| US-12146003-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2024-11-19 | — | — | US | disclosed |
| EP-3853305-B1 | HIGH-PURITY PEG LIPIDS AND USES THEREOF | MODERNATX INC (US) | 2024-10-02 | — | — | EP | disclosed |
| EP-4424697-A2 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | Bausch Health Ireland Limited (IE) | 2024-09-04 | — | — | EP | disclosed |
| EP-4422607-A1 | ORAL AND NASAL COMPOSITIONS AND METHODS OF TREATMENT | Aquestive Therapeutics, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| CN-112996854-B | High purity PEG lipids and uses thereof | 摩登纳特斯有限公司 | 2024-08-30 | — | — | CN | disclosed |
| US-20240287137-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | JPMORGAN CHASE BANK, N.A. | 2024-08-29 | — | — | US | disclosed |
| EP-3004138-B1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | BAUSCH HEALTH IRELAND LTD (IE) | 2024-03-13 | — | — | EP | disclosed |
| EP-3485881-B1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | HARVARD COLLEGE (US) | 2024-03-13 | — | — | EP | disclosed |
| US-11905525-B2 | Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins | MODERNATX, INC. (US) | 2024-02-20 | — | — | US | disclosed |
| US-20240050317-A1 | SYSTEM AND METHOD FOR MAKING PERSONALIZED INDIVIDUAL UNIT DOSES CONTAINING PHARMACEUTICAL ACTIVES | AQUESTIVE THERAPEUTICS, INC. (US) | 2024-02-15 | — | — | US | disclosed |
| EP-4309673-A2 | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE | Bausch Health Ireland Limited (IE) | 2024-01-24 | — | — | EP | disclosed |
| EP-4304554-A1 | DOSAGE FORMS HAVING EQUIVALENT BIOCOMPARABLE PROFILES | Aquestive Therapeutics, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| US-20240002440-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS | JPMORGAN CHASE BANK, N.A. | 2024-01-04 | — | — | US | disclosed |
| US-20230414452-A1 | SYSTEM AND METHOD FOR MAKING PERSONALIZED INDIVIDUAL UNIT DOSES CONTAINING PHARMACEUTICAL ACTIVES | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | US | disclosed |
| EP-3665216-B1 | METHOD FOR STABILIZING AQUEOUS DISPERSIONS OF FLUORINATED POLYMERS | SOLVAY SPECIALTY POLYMERS IT (IT) | 2023-12-13 | — | — | EP | disclosed |
| US-11834521-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2023-12-05 | — | — | US | disclosed |
| EP-4277611-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | Aquestive Therapeutics, Inc. (US) | 2023-11-22 | — | — | EP | disclosed |
| US-11806311-B2 | System and method for making personalized individual unit doses containing pharmaceutical actives | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230340023-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | JPMORGAN CHASE BANK, N.A. | 2023-10-26 | — | — | US | disclosed |
| CN-116940351-A | Prodrug compositions and methods of treatment | 阿奎斯蒂弗医疗股份有限公司 | 2023-10-24 | — | — | CN | disclosed |
| EP-3708179-B1 | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE | BAUSCH HEALTH IRELAND LTD (IE) | 2023-10-04 | — | — | EP | disclosed |
| US-20230295617-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | WAVE LIFE SCIENCES LTD. (SG) | 2023-09-21 | — | — | US | disclosed |
| US-20230277448-A1 | CHEWABLE FORMULATIONS | ELANCO TIERGESUNDHEIT AG (CH) | 2023-09-07 | — | — | US | disclosed |
| EP-4208155-A1 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2023-07-12 | — | — | EP | disclosed |
| US-20230149304-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230145752-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| WO-2023076281-A1 | ORAL AND NASAL COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-20230131450-A1 | ORAL AND NASAL COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230059204-A1 | TRANSDERMAL MICRO-DOSING DELIVERY OF PHARMACEUTICAL AGENTS | Pike Therapeutics Inc. (CA) | 2023-02-23 | — | — | US | disclosed |
| EP-4135712-A1 | TRANSDERMAL MICRO-DOSING DELIVERY OF PSYCHEDELICS DERIVATIVES | Pike Therapeutics, Inc. (CA) | 2023-02-22 | — | — | EP | disclosed |
| WO-2023012691-A1 | TRANSDERMAL MICRO-DOSING DELIVERY OF PHARMACEUTICAL AGENTS | PIKE THERAPEUTICS, INC. (CA) | 2023-02-09 | — | — | WO | disclosed |
| US-11555094-B2 | Method for stabilizing aqueous dispersions of fluorinated polymers | SOLVAY SPECIALTY POLYMERS ITALY S.P.A. (IT) | 2023-01-17 | — | — | US | disclosed |
| US-11541002-B2 | Oral film compositions and dosage forms having precise active dissolution profiles | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220347117-A1 | DOSAGE FORMS HAVING EQUIVALENT BIOCOMPARABLE PROFILES | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION | 2022-11-03 | — | — | US | disclosed |
| EP-4058029-A1 | MULTIMODAL COMPOSITIONS AND METHODS OF TREATMENT | Aquestive Therapeutics, Inc. (US) | 2022-09-21 | — | — | EP | disclosed |
| WO-2022192476-A1 | DOSAGE FORMS HAVING EQUIVALENT BIOCOMPARABLE PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| WO-2022187556-A1 | THERAPEUTIC METHODS AND COMPOSITIONS COMPRISING MAGNETIZABLE NANOPARTICLES | VRG STEM CELL SERVICES INC. (US) | 2022-09-09 | — | — | WO | disclosed |
| EP-4051235-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | Aquestive Therapeutics, Inc. (US) | 2022-09-07 | — | — | EP | disclosed |
| US-20220265857-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2022-08-25 | — | — | US | disclosed |
| US-20220241189-A1 | MODIFIED RELEASE DRUG POWDER COMPOSITION COMPRISING GASTRO-RETENTIVE RAFT FORMING SYSTEMS HAVING TRIGGER PULSE DRUG RELEASE | PROVIDENT BANK | 2022-08-04 | — | — | US | disclosed |
| US-20220233471-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | US | disclosed |
| WO-2022155544-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2022-07-21 | — | — | WO | disclosed |
| US-11337919-B2 | Modified release drug powder composition comprising gastro-retentive RAFT forming systems having trigger pulse drug release | TRIS PHARMA, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-11319346-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2022-05-03 | — | — | US | disclosed |
| US-20220119449-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | BAUSCH HEALTH IRELAND LIMITED (IE) | 2022-04-21 | — | — | US | disclosed |
| EP-3386484-B1 | COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX INC (US) | 2022-03-30 | — | — | EP | disclosed |
| US-11285222-B2 | Compositions and methods for delivery of agents | MODERNATX, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| WO-2022049149-A1 | CHEWABLE FORMULATIONS | ELANCO TIERGESUNDHEIT AG (CH) | 2022-03-10 | — | — | WO | disclosed |
| US-20220031631-A1 | HIGH-PURITY PEG LIPIDS AND USES THEREOF | MODERNATX, INC. (US) | 2022-02-03 | — | — | US | disclosed |
| US-20210403508-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | JPMORGAN CHASE BANK, N.A. | 2021-12-30 | — | — | US | disclosed |
| US-20210322447-A1 | TRANSDERMAL MICRO-DOSING DELIVERY OF PSYCHEDELICS DERIVATIVES | PIKE THERAPEUTICS INC (CA) | 2021-10-21 | — | — | US | disclosed |
| WO-2021209815-A1 | TRANSDERMAL MICRO-DOSING DELIVERY OF PSYCHEDELICS DERIVATIVES | PIKE THERAPEUTICS, INC. (CA) | 2021-10-21 | — | — | WO | disclosed |
| US-11142549-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2021-10-12 | — | — | US | disclosed |
| US-20210290771-A1 | ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-09-23 | — | — | US | disclosed |
| US-20210205406-A1 | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE | BAUSCH HEALTH IRELAND LIMITED (IE) | 2021-07-08 | — | — | US | disclosed |
| WO-2021097247-A1 | MULTIMODAL COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| US-20210145731-A1 | MULTIMODAL COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2021-05-20 | — | — | US | disclosed |
| US-11000597-B2 | Engineered receptor/ligand system for delivery of therapeutic agents | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-05-11 | — | — | US | disclosed |
| WO-2021087359-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
| US-20210128511-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2021-05-06 | — | — | US | disclosed |
| EP-3811371-A1 | SYSTEM AND METHOD FOR MAKING PERSONALIZED INDIVIDUAL UNIT DOSES CONTAINING PHARMACEUTICAL ACTIVES | Aquestive Therapeutics, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| US-20210015744-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A FLOATING INTERPENETRATING POLYMER NETWORK FORMING SYSTEM | PROVIDENT BANK | 2021-01-21 | — | — | US | disclosed |
| US-20210015745-A1 | MODIFIED RELEASE DRUG POWDER COMPOSITION COMPRISING GASTRO-RETENTIVE RAFT FORMING SYSTEMS HAVING TRIGGER PULSE DRUG RELEASE | PROVIDENT BANK | 2021-01-21 | — | — | US | disclosed |
| US-20200399315-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | JPMORGAN CHASE BANK, N.A. | 2020-12-24 | — | — | US | disclosed |
| US-20200384068-A1 | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE | BAUSCH HEALTH IRELAND LTD (IE) | 2020-12-10 | — | — | US | disclosed |
| EP-3740188-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A FLOATING INTERPENETRATING POLYMER NETWORK FORMING SYSTEM | Tris Pharma, Inc. (US) | 2020-11-25 | — | — | EP | disclosed |
| EP-3740189-A1 | MODIFIED RELEASE DRUG POWDER COMPOSITION COMPRISING GASTRO-RETENTIVE RAFT FORMING SYSTEMS HAVING TRIGGER PULSE DRUG RELEASE | Tris Pharma, Inc. (US) | 2020-11-25 | — | — | EP | disclosed |
| US-20200345624-A1 | Nanopore Delivery Device | HUDSON LEE EDWARD (US) | 2020-11-05 | — | — | US | disclosed |
| EP-3708179-A1 | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE | Bausch Health Ireland Limited (IE) | 2020-09-16 | — | — | EP | disclosed |
| US-20200283480-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS | BAUSCH HEALTH COMPANIES INC. (CA) | 2020-09-10 | — | — | US | disclosed |
| US-10745441-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2020-08-18 | — | — | US | disclosed |
| US-10711038-B2 | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders | BAUSCH HEALTH IRELAND LIMITED (IE) | 2020-07-14 | — | — | US | disclosed |
| US-20200113968-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR DOWNREGULATION OF PRO-INFLAMMATORY CYTOKINES | BAUSCH HEALTH IRELAND LTD (IE) | 2020-04-16 | — | — | US | disclosed |
| US-20200101009-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION | 2020-04-02 | — | — | US | disclosed |
| US-10597424-B2 | Agonists of guanylate cyclase and their uses | BAUSCH HEALTH IRELAND LIMITED (IE) | 2020-03-24 | — | — | US | disclosed |
| EP-2825188-B1 | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE | BAUSCH HEALTH IRELAND LTD (IE) | 2020-03-04 | — | — | EP | disclosed |
| US-20200040038-A1 | Process of Preparing Guanylate Cyclase C Agonists | BAUSCH HEALTH IRELAND LTD (IE) | 2020-02-06 | — | — | US | disclosed |
| US-20190321439-A1 | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE | BAUSCH HEALTH IRELAND LTD (IE) | 2019-10-24 | — | — | US | disclosed |
| US-10421787-B2 | Process of preparing guanylate cyclase C agonisys | BAUSCH HEALTH IRELAND LIMITED (IE) | 2019-09-24 | — | — | US | disclosed |
| US-20190262420-A1 | COMPOSITIONS USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | SYNERGY PHARMACEUTICALS INC (US) | 2019-08-29 | — | — | US | disclosed |
| US-20190263861-A1 | AGONISTS OF GUANYLATE CYCLASE AND THEIR USES | JPMORGAN CHASE BANK, N.A. | 2019-08-29 | — | — | US | disclosed |
| US-20190249173-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | WAVE LIFE SCIENCES LTD. (SG) | 2019-08-15 | — | — | US | disclosed |
| US-10369340-B2 | Device and method for sustained release of low water solubility therapeutic agent in solubilizer | NANOMEDICAL SYSTEMS, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| EP-2419091-B1 | NANOCHANNELED DEVICE AND RELATED METHODS | UNIV TEXAS (US) | 2019-06-26 | — | — | EP | disclosed |
| US-10238712-B2 | Compositions useful for the treatment of gastrointestinal disorders | SYNERGY PHARMACEUTICALS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| EP-3239170-B1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS | SYNERGY PHARMACEUTICALS INC (US) | 2019-03-20 | — | — | EP | disclosed |
| US-10232011-B2 | Formulations of guanylate cyclase C agonists and methods of use | SYNERGY PHARMACEUTICALS, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| EP-3452597-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | Wave Life Sciences Ltd. (SG) | 2019-03-13 | — | — | EP | disclosed |
| CN-109462995-A | The method and composition of bioactivator | 波涛生命科学有限公司 | 2019-03-12 | — | — | CN | disclosed |
| US-20190054024-A1 | Solid Dosage Forms | HUMANWELL PHARMACEUTICAL US, Inc. (US) | 2019-02-21 | — | — | US | disclosed |
| US-20190002501-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | JPMORGAN CHASE BANK, N.A. | 2019-01-03 | — | — | US | disclosed |
| US-10118946-B2 | Agonists of guanylate cyclase and their uses | SYNERGY PHARMACEUTICALS INC. (US) | 2018-11-06 | — | — | US | disclosed |
| US-20180273586-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS | SYNERGY PHARMACEUTICALS INC. | 2018-09-27 | — | — | US | disclosed |
| EP-3366698-A1 | GUANYLATE CYCLASE C AGONISTS | Synergy Pharmaceuticals Inc. (US) | 2018-08-29 | — | — | EP | disclosed |
| EP-3357502-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF COLON CANCER | Synergy Pharmaceuticals Inc. (US) | 2018-08-08 | — | — | EP | disclosed |
| US-20180207229-A1 | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE | JPMORGAN CHASE BANK, N.A. | 2018-07-26 | — | — | US | disclosed |
| US-10011637-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | SYNERGY PHARMACEUTICALS, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-9925231-B2 | Formulations of guanylate cyclase C agonists and methods of use | SYNERGY PHARMACEUTICALS, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-9919024-B2 | Formulations of guanylate cyclase C agonists and methods of use | SYNERGY PHARMACEUTICALS, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-9920095-B2 | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders | SYNERGY PHARMACEUTICALS, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-9914752-B2 | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders | SYNERGY PHARMACEUTICALS, INC. (US) | 2018-03-13 | — | — | US | disclosed |
| US-20180015172-A1 | ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2018-01-18 | — | — | US | disclosed |
| CN-104546669-B | Nanochannel device and correlation technique | 得克萨斯大学体系董事会 | 2018-01-05 | — | — | CN | disclosed |
| EP-2681236-B1 | PROCESS OF PREPARING GUANYLATE CYCLASE C AGONISTS | SYNERGY PHARMACEUTICALS INC (US) | 2018-01-03 | — | — | EP | disclosed |
| US-20170349630-A1 | AGONISTS OF GUANYLATE CYCLASE AND THEIR USES | JPMORGAN CHASE BANK, N.A. | 2017-12-07 | — | — | US | disclosed |
| US-9814752-B2 | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases | SYNERGY PHARMACEUTICALS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170319698-A1 | GASTRORETENTIVE GEL FORMULATIONS | JAGOTEC AG (CH) | 2017-11-09 | — | — | US | disclosed |
| WO-2017192679-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | WAVE LIFE SCIENCES LTD. (SG) | 2017-11-09 | — | — | WO | disclosed |
| EP-3241839-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL, INFLAMMATION, CANCER AND OTHER DISORDERS | Synergy Pharmaceuticals Inc. (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-3239170-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS | Synergy Pharmaceuticals Inc. (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-3212167-A1 | GASTRORETENTIVE GEL FORMULATIONS | Jagotec AG (CH) | 2017-09-06 | — | — | EP | disclosed |
| CN-107106484-A | Gastric retention gel preparation | 雅戈泰克股份公司 | 2017-08-29 | — | — | CN | disclosed |
| US-20170216314-A1 | TOPICAL FORMULATIONS | NUVO RESEARCH INC. (CA) | 2017-08-03 | — | — | US | disclosed |
| US-20170209531-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS | JPMORGAN CHASE BANK, N.A. | 2017-07-27 | — | — | US | disclosed |
| US-20170202904-A1 | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE | JPMORGAN CHASE BANK, N.A. | 2017-07-20 | — | — | US | disclosed |
| US-20170202903-A1 | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE | JPMORGAN CHASE BANK, N.A. | 2017-07-20 | — | — | US | disclosed |
| US-9708367-B2 | Agonists of guanylate cyclase and their uses | SYNERGY PHARMACEUTICALS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20170129925-A1 | PROCESS OF PREPARING GUANYLATE CYCLASE C AGONISYS | SYNERGY PHARMACEUTICALS INC. (US) | 2017-05-11 | — | — | US | disclosed |
| US-9642912-B2 | Topical formulations for treating skin conditions | CRESCITA THERAPEUTICS INC. (CA) | 2017-05-09 | — | — | US | disclosed |
| US-9616097-B2 | Formulations of guanylate cyclase C agonists and methods of use | SYNERGY PHARMACEUTICALS, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9610321-B2 | Formulations of guanylate cyclase C agonists and methods of use | SYNERGY PHARMACEUTICALS, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| EP-2810951-B1 | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders | SYNERGY PHARMACEUTICALS INC (US) | 2017-03-15 | — | — | EP | disclosed |
| US-9580471-B2 | Process of preparing guanylate cyclase C agonists | SYNERGY PHARMACEUTICALS, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| EP-2321341-B1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL, INFLAMMATION, CANCER AND OTHER DISORDERS | SYNERGY PHARMACEUTICALS INC (US) | 2017-02-22 | — | — | EP | disclosed |
| US-20170029468-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS | SYNERGY PHARMACEUTICALS INC. | 2017-02-02 | — | — | US | disclosed |
| US-20170000843-A1 | COMPOSITIONS USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | BAUSCH HEALTH, CANADA INC. (CA) | 2017-01-05 | — | — | US | disclosed |
| US-9526824-B2 | Nanochanneled device and related methods | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-12-27 | — | — | US | disclosed |
| US-20160367623-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS | SYNERGY PHARMACEUTICALS INC. | 2016-12-22 | — | — | US | disclosed |
| US-9505805-B2 | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders | SYNERGY PHARMACEUTICALS, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160340390-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS | SYNERGY PHARMACEUTICALS INC (US) | 2016-11-24 | — | — | US | disclosed |
| EP-2355864-B1 | NANOCHANNELED DEVICE AND RELATED METHODS | UNIV TEXAS (US) | 2016-11-09 | — | — | EP | disclosed |
| US-9486494-B2 | Compositions useful for the treatment of gastrointestinal disorders | SYNERGY PHARMACEUTICALS, INC. (US) | 2016-11-08 | — | — | US | disclosed |
| CN-105963676-A | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases | 药物协和股份有限公司 | 2016-09-28 | — | — | CN | disclosed |
| EP-3065757-A2 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR DOWNREGULATION OF PRO-INFLAMMATORY CYTOKINES | Synergy Pharmaceuticals Inc. (US) | 2016-09-14 | — | — | EP | disclosed |
| US-20160243188-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS | JPMORGAN CHASE BANK, N.A. | 2016-08-25 | — | — | US | disclosed |
| US-20160235807-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR DOWNREGULATION OF PRO-INFLAMMATORY CYTOKINES | SYNERGY PHARMACEUTICALS INC. | 2016-08-18 | — | — | US | disclosed |
| WO-2016118787-A1 | ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2016-07-28 | — | — | WO | disclosed |
| US-20160200766-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS | SOLTA MEDICAL IRELAND LIMITED (IE) | 2016-07-14 | — | — | US | disclosed |
| CN-103601792-B | It is effective to the guanylate cyclase agonist of gastrointestinal dysfunction, inflammation, cancer and other diseases treatment | 协同医药品公司 | 2016-06-29 | — | — | CN | disclosed |
| US-20160175572-A1 | DEVICE AND METHOD FOR SUSTAINED RELEASE OF LOW WATER SOLUBILITY THERAPEUTIC AGENT IN SOLUBILIZER | NANOMEDICAL SYSTEMS, INC. (US) | 2016-06-23 | — | — | US | disclosed |
| EP-3033138-A1 | DEVICE AND METHOD FOR SUSTAINED RELEASE OF LOW WATER SOLUBILITY THERAPEUTIC AGENT IN SOLUBILIZER | Nanomedical Systems Inc. (US) | 2016-06-22 | — | — | EP | disclosed |
| US-20160145307-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | JPMORGAN CHASE BANK, N.A. | 2016-05-26 | — | — | US | disclosed |
| WO-2016066256-A1 | GASTRORETENTIVE GEL FORMULATIONS | JAGOTEC AG (CH) | 2016-05-06 | — | — | WO | disclosed |
| EP-3004138-A2 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | Synergy Pharmaceuticals Inc. (US) | 2016-04-13 | — | — | EP | disclosed |
| US-9308181-B2 | Topical formulations, systems and methods | NUVO RESEARCH INC. (CA) | 2016-04-12 | — | — | US | disclosed |
| US-9308162-B2 | Biocompatible oligomer-polymer compositions | TOLMAR THERAPEUTICS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| EP-2998314-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS | Synergy Pharmaceuticals Inc. (US) | 2016-03-23 | — | — | EP | disclosed |
| US-9278134-B2 | Dual functioning ionic liquids and salts thereof | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2016-03-08 | — | — | US | disclosed |
| US-9266926-B2 | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders | SYNERGY PHARMACEUTICALS, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| EP-2968439-A2 | COMPOSITIONS USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | Synergy Pharmaceuticals Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2970384-A1 | AGONISTS OF GUANYLATE CYCLASE AND THEIR USES | Synergy Pharmaceuticals Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9238677-B2 | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders | SYNERGY PHARMACEUTICALS, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| US-20150366935-A1 | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE | JPMORGAN CHASE BANK, N.A. | 2015-12-24 | — | — | US | disclosed |
| EP-2205639-B1 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | MERCK SHARP & DOHME (US) | 2015-12-23 | — | — | EP | disclosed |
| WO-2015167760-A1 | DRUG DELIVERY VEHICLES COMPRISING CELLULOSE DERIVATIVES, STARCH DERIVATIVES, AND COMBINATIONS THEREOF | CELANESE ACETATE LLC (US) | 2015-11-05 | — | — | WO | disclosed |
| US-20150306230-A1 | DRUG DELIVERY VEHICLES COMPRISING CELLULOSE DERIVATIVES, STARCH DERIVATIVES, AND COMBINATIONS THEREOF | CELANESE ACETATE LLC (US) | 2015-10-29 | — | — | US | disclosed |
| EP-2527360-B1 | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders | SYNERGY PHARMACEUTICALS INC (US) | 2015-10-28 | — | — | EP | disclosed |
| US-20150297723-A1 | TOPICAL FORMULATIONS FOR TREATING SKIN CONDITIONS | NUVO RESEARCH INC. (CA) | 2015-10-22 | — | — | US | disclosed |
| US-20150283202-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA, ATHEROSCLEROSIS, CORONARY HEART DISEASE, GALLSTONE, OBESITY AND OTHER CARDIOVASCULAR DISEASES | BAUSCH HEALTH COMPANIES INC. (CA) | 2015-10-08 | — | — | US | disclosed |
| US-20150273013-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS | SYNERGY PHARMACEUTICALS INC (US) | 2015-10-01 | — | — | US | disclosed |
| EP-2923706-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | Synergy Pharmaceuticals Inc. (US) | 2015-09-30 | — | — | EP | disclosed |
| US-20150246174-A1 | NANOCHANNELED DEVICE AND RELATED METHODS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-09-03 | — | — | US | disclosed |
| EP-2296685-B1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS | SYNERGY PHARMACEUTICALS INC (US) | 2015-09-02 | — | — | EP | disclosed |
| EP-2912070-A1 | POLYSACCHARIDE ESTER MICROSPHERES AND METHODS AND ARTICLES RELATING THERETO | Celanese Acetate LLC (US) | 2015-09-02 | — | — | EP | disclosed |
| US-20150239934-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS | SOLTA MEDICAL IRELAND LIMITED (IE) | 2015-08-27 | — | — | US | disclosed |
| US-9096743-B2 | Process for forming films, fibers, and beads from chitinous biomass | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2015-08-04 | — | — | US | disclosed |
| CN-104812777-A | Polysaccharide ester microspheres and methods and articles related thereto | CELANESE ACETATE LLC | 2015-07-29 | — | — | CN | disclosed |
| US-9089612-B2 | Method of inhibiting bile acid absorption by administering an agonist of a guanylate cyclase receptor | SYNERGY PHARMACEUTICALS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9089522-B2 | Method of reducing total cholesterol level by administering matrilin-2 polypeptide | MERCK SHARP & DOHME CORP. (US) | 2015-07-28 | — | — | US | disclosed |
| CN-104546669-A | NANOCHANNELED DEVICE AND RELATED METHODS | UNIV TEXAS | 2015-04-29 | — | — | CN | disclosed |
| US-9005185-B2 | Nanochanneled device and related methods | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-04-14 | — | — | US | disclosed |
| EP-2506865-B1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | SYNERGY PHARMACEUTICALS INC (US) | 2015-04-01 | — | — | EP | disclosed |
| US-8969514-B2 | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases | SYNERGY PHARMACEUTICALS, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20150057235-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS | JPMORGAN CHASE BANK, N.A. | 2015-02-26 | — | — | US | disclosed |
| WO-2015023557-A1 | DEVICE AND METHOD FOR SUSTAINED RELEASE OF LOW WATER SOLUBILITY THERAPEUTIC AGENT IN SOLUBILIZER | NANOMEDICAL SYSTEMS, INC. (US) | 2015-02-19 | — | — | WO | disclosed |
| EP-2291174-B1 | FLOWABLE COMPOSITION COMPRISING BIOCOMPATIBLE OLIGOMER-POLYMER COMPOSITIONS | TOLMAR THERAPEUTICS INC (US) | 2015-01-28 | — | — | EP | disclosed |
| EP-2825188-A1 | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE | Synergy Pharmaceuticals Inc. (US) | 2015-01-21 | — | — | EP | disclosed |
| CN-102271732-B | Nanochannel devices and related methods | UNIV TEXAS | 2014-12-31 | — | — | CN | disclosed |
| WO-2014197720-A2 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | SYNERGY PHARMACEUTICALS, INC. (US) | 2014-12-11 | — | — | WO | disclosed |
| EP-2810951-A2 | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders | Synergy Pharmaceuticals Inc. (US) | 2014-12-10 | — | — | EP | disclosed |
| CN-104203220-A | Device and method for sustained release of therapeutic agent | UNIV TEXAS | 2014-12-10 | — | — | CN | disclosed |
| US-8901075-B2 | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders | SYNERGY PHARMACEUTICALS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20140348936-A1 | GASTRORETENTIVE CONTROLLED RELEASE VEHICLES THAT INCLUDE ETHYLENE COPOLYMERS, ETHYL CELLULOSES, AND/OR THERMOPLASTIC POLYURETHANES | CELANESE EVA PERFORMANCE POLYMERS, INC. | 2014-11-27 | — | — | US | disclosed |
| US-20140328884-A1 | CONTROLLED RELEASE VEHICLES HAVING DESIRED VOID VOLUME ARCHITECTURES | CELANESE EVA PERFORMANCE POLYMERS, INC. | 2014-11-06 | — | — | US | disclosed |
| US-20140329738-A1 | Agonists of Guanylate Cyclase Useful For the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders | JPMORGAN CHASE BANK, N.A. | 2014-11-06 | — | — | US | disclosed |
| US-20140315720-A1 | POLYSACCHARIDE ESTER MICROSPHERES AND METHODS AND ARTICLES RELATING THERETO | CELANESE ACETATE LLC (US) | 2014-10-23 | — | — | US | disclosed |
| EP-2790677-A1 | CONTROLLED RELEASE VEHICLES HAVING DESIRED VOID VOLUME ARCHITECTURES | Celanese Eva Performance Polymers, Inc. (US) | 2014-10-22 | — | — | EP | disclosed |
| EP-2790678-A1 | GASTRORETENTIVE CONTROLLED RELEASE VEHICLES THAT INCLUDE ETHYLENE COPOLYMERS, ETHYL CELLULOSES, AND/OR THERMPOPLASTIC POLYURETHANES | Celanese Eva Performance Polymers, Inc. (US) | 2014-10-22 | — | — | EP | disclosed |
| EP-1813611-B1 | 1-SUBSTITUTED-3- BETA-D-GLYCOPYRANOSYLATED NITROGENOUS HETERO- CYCLIC COMPOUNDS AND MEDICINES CONTAINING THE SAME | KISSEI PHARMACEUTICAL (JP) | 2014-10-01 | — | — | EP | disclosed |
| WO-2014151200-A2 | COMPOSITIONS USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | SYNERGY PHARMACEUTICALS INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014151206-A1 | AGONISTS OF GUANYLATE CYCLASE AND THEIR USES | SYNERGY PHARMACEUTICALS INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140287001-A1 | Compositions Useful For The Treatment Of Gastrointestinal Disorders | BAUSCH HEALTH IRELAND LIMITED (IE) | 2014-09-25 | — | — | US | disclosed |
| US-20140287002-A1 | Agonists Of Guanylate Cyclase And Their Uses | JPMORGAN CHASE BANK, N.A. | 2014-09-25 | — | — | US | disclosed |
| EP-2770984-A1 | DEVICE AND METHOD FOR SUSTAINED RELEASE OF THERAPEUTIC AGENT | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-09-03 | — | — | EP | disclosed |
| US-8802596-B2 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2014-08-12 | — | — | US | disclosed |
| EP-2328910-B1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS | SYNERGY PHARMACEUTICALS INC (US) | 2014-08-06 | — | — | EP | disclosed |
| US-8779090-B2 | Methods and compositions for the treatment of heart failure and other disorders | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20140187470-A1 | Agonists of Guanylate Cyclase Useful For the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders | SYNERGY PHARMACEUTICALS, INC. | 2014-07-03 | — | — | US | disclosed |
| US-20140180251-A1 | NANOCHANNELED DEVICE AND RELATED METHODS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140161798-A1 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | MERCK SHARP & DOHME CORP. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140155575-A1 | Process of Preparing Guanylate Cyclase C Agonists | SYNERGY PHARMACEUTICALS INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140135274-A1 | Agonists of Guanylate Cyclase Useful For the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders | SYNERGY PHARMACEUTICALS, INC. | 2014-05-15 | — | — | US | disclosed |
| EP-1724278-B1 | NITROGENOUS FUSED-RING DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE DERIVATIVES, AND USE THEREOF AS DRUGS | KISSEI PHARMACEUTICAL (JP) | 2014-05-07 | — | — | EP | disclosed |
| US-8716224-B2 | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders | SYNERGY PHARMACEUTICALS INC. (US) | 2014-05-06 | — | — | US | disclosed |
| WO-2014066463-A1 | POLYSACCHARIDE ESTER MICROSPHERES AND METHODS AND ARTICLES RELATING THERETO | CELANESE ACETATE LLC (US) | 2014-05-01 | — | — | WO | disclosed |
| CN-103764672-A | Process for preparing guanylate cyclase C agonists | SYNERGY PHARMACEUTICALS INC | 2014-04-30 | — | — | CN | disclosed |
| US-20140113826-A1 | POLYSACCHARIDE ESTER MICROSPHERES AND METHODS AND ARTICLES RELATING THERETO | CELANESE ACETATE LLC (US) | 2014-04-24 | — | — | US | disclosed |
| US-8664354-B2 | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders | SYNERGY PHARMACEUTICALS INC. (US) | 2014-03-04 | — | — | US | disclosed |
| WO-2014031398-A1 | BIOMEDICAL DEVICES COMPRISING MOLDED POLYETHYLENE COMPONENTS | TICONA LLC (US) | 2014-02-27 | — | — | WO | disclosed |
| CN-103601792-A | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders | SYNERGY PHARMACEUTICALS INC | 2014-02-26 | — | — | CN | disclosed |
| US-20140052264-A1 | Porous, Stabilized Craniomaxillofacial Implants and Methods and Kits Relating Thereto | TICONA LLC (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140051771-A1 | Biomedical Devices Comprising Molded Polyethylene Components | TICONA LLC (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140024605-A1 | Agonists of Guanylate Cyclase Useful For the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders | SYNERGY PHARMACEUTICALS INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-8632510-B2 | Nanochanneled device and related methods | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-01-21 | — | — | US | disclosed |
| EP-2681236-A2 | PROCESS OF PREPARING GUANYLATE CYCLASE C AGONISTS | Synergy Pharmaceuticals Inc. (US) | 2014-01-08 | — | — | EP | disclosed |
| US-8623873-B2 | Substituted piperazines as CB1 antagonists | INTERVET INC. (US) | 2014-01-07 | — | — | US | disclosed |
| EP-1810971-B1 | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia | MERCK SHARP & DOHME (US) | 2013-12-25 | — | — | EP | disclosed |
| US-20130337031-A1 | TOPICAL FORMULATIONS, SYSTEMS AND METHODS | NUVO RESEARCH INC. (CA) | 2013-12-19 | — | — | US | disclosed |
| EP-2671584-A2 | Compositions and methods for treating disorders associated with salt or fluid retention | Ironwood Pharmaceuticals, Inc. (US) | 2013-12-11 | — | — | EP | disclosed |
| US-8598320-B2 | Anti-PCSK9 and methods for treating lipid and cholesterol disorders | MERCK SHARP & DOHME CORP. (US) | 2013-12-03 | — | — | US | disclosed |
| US-20130310328-A1 | Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders | BAUSCH HEALTH, CANADA INC. (CA) | 2013-11-21 | — | — | US | disclosed |
| EP-2527360-A9 | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders | Synergy Pharmaceuticals Inc. (US) | 2013-11-13 | — | — | EP | disclosed |
| CN-101772513-B | Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and other diseases | SYNERGY PHARMACEUTICALS INC | 2013-11-13 | — | — | CN | disclosed |
| US-8569246-B2 | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders | Synergy Pharamaceuticals Inc. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20130274204-A1 | Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders | SYNERGY PHARMACEUTICALS, INC. | 2013-10-17 | — | — | US | disclosed |
| EP-2650303-A1 | Methods and compositions for the treatment of heart failure and other disorders | Ironwood Pharmaceuticals, Inc. (US) | 2013-10-16 | — | — | EP | disclosed |
| EP-2170930-B3 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS | SYNERGY PHARMACEUTICALS INC (US) | 2013-10-02 | — | — | EP | disclosed |
| EP-1606287-B1 | SUBSTITUTED AZETIDINONE COMPOUNDS, FORMULATIONS AND USES THEREOF FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | MERCK SHARP & DOHME (US) | 2013-10-02 | — | — | EP | disclosed |
| WO-2013138352-A1 | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE | SYNERGY PHARMACEUTICALS INC. (US) | 2013-09-19 | — | — | WO | disclosed |
| US-20130240483-A1 | NANOCHANNELED DEVICE AND RELATED METHODS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-09-19 | — | — | US | disclosed |
| CN-103271083-A | Multi-functional ionic liquid compositions | UNIV ALABAMA | 2013-09-04 | — | — | CN | disclosed |
| US-8513304-B2 | Topical formulation | NUVO RESEARCH INC. (CA) | 2013-08-20 | — | — | US | disclosed |
| EP-2621509-A2 | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE | Synergy Pharmaceuticals Inc. (US) | 2013-08-07 | — | — | EP | disclosed |
| US-8497348-B2 | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders | SYNERGY PHARMACEUTICALS INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-8480637-B2 | Nanochanneled device and related methods | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-07-09 | — | — | US | disclosed |
| CN-101657471-B | Bicyclic compounds and their use as antidiabetics | SMITHKLINE BEECHAM CORP | 2013-07-03 | — | — | CN | disclosed |
| WO-2013090891-A1 | CONTROLLED RELEASE VEHICLES HAVING DESIRED VOID VOLUME ARCHITECTURES | CELANESE EVA PERFORMANCE POLYMERS, INC. (US) | 2013-06-20 | — | — | WO | disclosed |
| WO-2013090893-A1 | GASTRORETENTIVE CONTROLLED RELEASE VEHICLES THAT INCLUDE ETHYLENE COPOLYMERS, ETHYL CELLULOSES, AND/OR THERMPOPLASTIC POLYURETHANES | CELANESE EVA PERFORMANCE POLYMERS, INC. (US) | 2013-06-20 | — | — | WO | disclosed |
| CN-101326275-B | Multifunctional ionic liquid composition | UNIV ALABAMA | 2013-06-05 | — | — | CN | disclosed |
| US-20130131628-A1 | DEVICE AND METHOD FOR SUSTAINED RELEASE OF THERAPEUTIC AGENT | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-05-23 | — | — | US | disclosed |
| WO-2013063004-A1 | DEVICE AND METHOD FOR SUSTAINED RELEASE OF THERAPEUTIC AGENT | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-05-02 | — | — | WO | disclosed |
| US-20130096071-A1 | Agonists of Guanylate Cyclase Useful For the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders | SYNERGY PHARMACEUTICALS INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130079404-A1 | TOPICAL FORMULATION | NUVO RESEARCH INC. (CA) | 2013-03-28 | — | — | US | disclosed |
| US-20130072468-A1 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | GILBERT ERIC J (US) | 2013-03-21 | — | — | US | disclosed |
| US-8367800-B2 | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders | SYNERGY PHARMACEUTICALS INC. (US) | 2013-02-05 | — | — | US | disclosed |
| EP-2548874-A2 | Substituted piperazines as CB1 antagonists | Intervet International B.V. (NL) | 2013-01-23 | — | — | EP | disclosed |
| US-8357775-B2 | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders | SYNERGY PHARMACEUTICALS, INC. | 2013-01-22 | — | — | US | disclosed |
| CN-102858361-A | Agonists of guanylate cyclase for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstones, obesity and other cardiovascular diseases | SYNERGY PHARMACEUTICALS INC | 2013-01-02 | — | — | CN | disclosed |
| US-8343962-B2 | Topical formulation | NUVO RESEARCH INC. (CA) | 2013-01-01 | — | — | US | disclosed |
| US-8324176-B2 | Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-12-04 | — | — | US | disclosed |
| EP-2527360-A2 | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders | Synergy Pharmaceuticals Inc. (US) | 2012-11-28 | — | — | EP | disclosed |
| US-8314077-B2 | Fatty acid-pharmaceutical agent conjugates | LUITPOLD PHARMACEUTICALS, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-20120289460-A1 | Agonists of Guanylate Cyclase Useful for the Treatment of Hypercholesterolemia, Atherosclerosis, Coronary Heart Disease, Gallstone, Obesity and Other Cardiovascular Diseases | SYNERGY PHARMACEUTICALS INC. (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120283411-A9 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120264605-A1 | Multi-Functional Ionic Liquid Compositions for Overcoming Polymorphism and Imparting Improved Properties for Active Pharmaceutical, Biological, Nutritional, and Energetic Ingredients | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120237593-A1 | Formulations of Guanylate Cyclase C Agonists and Methods of Use | SYNERGY PHARMACEUTICALS INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | disclosed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | disclosed |
| WO-2012118972-A2 | PROCESS OF PREPARING GUANYLATE CYCLASE C AGONISTS | SYNEGY PHARMACEUTICALS INC. (US) | 2012-09-07 | — | — | WO | disclosed |
| US-8257921-B1 | NRIP1 regulation of apolipoprotein A1 | SCHERING CORPORATION (US) | 2012-09-04 | — | — | US | disclosed |
| US-20120220526-A1 | Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and other Disorders | SYNERGY PHARMACEUTICALS, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| EP-2170930-B1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS | SYNERGY PHARMACEUTICALS INC (US) | 2012-08-15 | — | — | EP | disclosed |
| US-8236805-B2 | Substituted piperazines as CB1 antagonists | INTERVET INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-8232265-B2 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2012-07-31 | — | — | US | disclosed |
| US-8222261-B2 | Chemical compounds | GlaxoSmithKline, LLC (US) | 2012-07-17 | — | — | US | disclosed |
| US-8207295-B2 | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders | SYNERGY PHARMACEUTICALS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| EP-1548024-B1 | PYRAZOLE DERIVATIVES, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF | KISSEI PHARMACEUTICAL (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20120115729-A1 | PROCESS FOR FORMING FILMS, FIBERS, AND BEADS FROM CHITINOUS BIOMASS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2012-05-10 | — | — | US | disclosed |
| EP-1609798-B1 | FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | KISSEI PHARMACEUTICAL (JP) | 2012-05-09 | — | — | EP | disclosed |
| WO-2012054438-A1 | ANTI-PCSK9 | SCHERING CORPORATION (US) | 2012-04-26 | — | — | WO | disclosed |
| US-20120095443-A1 | NANOCHANNELED DEVICE AND RELATED METHODS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120088902-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-20120077812-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | FANG JING (US) | 2012-03-29 | — | — | US | disclosed |
| WO-2012037380-A2 | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE | SYNERGY PHARMACEUTICALS INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| US-20120046244-A1 | DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2012-02-23 | — | — | US | disclosed |
| EP-2419091-A2 | NANOCHANNELED DEVICE AND RELATED METHODS | The Board of Regents of The University of Texas System (US) | 2012-02-22 | — | — | EP | disclosed |
| US-20120040892-A9 | Methods and Compositions for the Treatment of Heart Failure and Other Disorders | WELLS FARGO BANK, NATIONAL ASSOCIATION | 2012-02-16 | — | — | US | disclosed |
| US-8101634-B2 | Bicyclic compounds and use as antidiabetics | GLAXOSMITHKLINE LLC (US) | 2012-01-24 | — | — | US | disclosed |
| EP-1637539-B1 | PYRAZOLE DERIVATIVE, DRUG COMPOSITION CONTAINING THE SAME AND PRODUCTION INTERMEDIATE THEREFOR | KISSEI PHARMACEUTICAL (JP) | 2012-01-18 | — | — | EP | disclosed |
| EP-1609798-A9 | FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2012-01-11 | — | — | EP | disclosed |
| US-20110319343-A1 | Agonists Of Guanylate Cyclase Useful For The Treatment Of Gastrointestinal Disorders, Inflammation, Cancer And Other Disorders | SYNERGY PHARMACEUTICALS, INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-8058245-B2 | Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-11-15 | — | — | US | disclosed |
| CN-102232088-A | Anti-PCSK9 and methods for treating lipid and cholesterol disorders | SCHERING CORP | 2011-11-02 | — | — | CN | disclosed |
| EP-2094683-B1 | Bicyclic compounds and use as antidiabetics | GLAXOSMITHKLINE LLC (US) | 2011-10-12 | — | — | EP | disclosed |
| US-8034782-B2 | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders | SYNERGY PHARMACEUTICALS, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| US-20110245172-A1 | BIOCOMPATIBLE OLIGOMER-POLYMER COMPOSITIONS | TOLMAR THERAPEUTICS, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| EP-2355864-A2 | NANOCHANNELED DEVICE AND RELATED METHODS | The Board of Regents of The University of Texas System (US) | 2011-08-17 | — | — | EP | disclosed |
| US-7998975-B2 | Sodium dependent glucose transporter inhibition; hyperglycemia associated diseases; 3-glucopyranosyloxy- 1H-indazole and 1H-pyrazolo[3,4-b]pyridine derivatives | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-7989424-B2 | Glucopyranosyloxypyrazole derivatives and use thereof in medicines | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-08-02 | — | — | US | disclosed |
| US-7976871-B2 | Modified release composition of highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2011-07-12 | — | — | US | disclosed |
| US-20110160120-A1 | Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders | SYNERGY PHARMACEUTICALS INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110150875-A1 | EGF-A DOMAIN-MEDIATED MODULATION OF PCKS9 FOR TREATING LIPID DISORDERS | MERCK SHARP & DOHME CORP. | 2011-06-23 | — | — | US | disclosed |
| US-7960380-B2 | Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2011-06-14 | — | — | US | disclosed |
| EP-2328910-A2 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS | Synergy Pharmaceuticals Inc. (US) | 2011-06-08 | — | — | EP | disclosed |
| CN-1934103-B | Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof | KISSEI PHARMACEUTICAL | 2011-06-01 | — | — | CN | disclosed |
| US-20110124652-A1 | Chemical Compounds and Uses | SMITHKLINE BEECHAM CORPORATION | 2011-05-26 | — | — | US | disclosed |
| EP-2325182-A1 | Bicyclic compounds and use as antidiabetics | Glaxosmithkline LLC (US) | 2011-05-25 | — | — | EP | disclosed |
| EP-2321341-A2 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL, INFLAMMATION, CANCER AND OTHER DISORDERS | Synergy Pharmaceuticals Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| EP-2320910-A1 | CHEMICAL COMPOUNDS AND USES | GlaxoSmithKline LLC (US) | 2011-05-18 | — | — | EP | disclosed |
| US-7906502-B2 | 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions | ASTRAZENECA AB (SE) | 2011-03-15 | — | — | US | disclosed |
| EP-2291174-A1 | BIOCOMPATIBLE OLIGOMER-POLYMER COMPOSITIONS | Tolmar Therapeutics, Inc. (US) | 2011-03-09 | — | — | EP | disclosed |
| US-7897601-B2 | Cannabinoid receptor modulators | INTERVET, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| EP-2285399-A2 | EGF-A DOMAIN-MEDIATED MODULATION OF PCSK9 FOR TREATING LIPID DISORDERS | Schering Corporation (US) | 2011-02-23 | — | — | EP | disclosed |
| US-7893048-B2 | 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions | ASTRAZENECA AB (SE) | 2011-02-22 | — | — | US | disclosed |
| US-7888487-B2 | Pyrazole derivative, medicinal composition containing the same, medicinal use thereof and intermediate in producing the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-02-15 | — | — | US | disclosed |
| US-20110033465-A1 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | SCHERING CORPORATION (US) | 2011-02-10 | — | — | US | disclosed |
| US-20110028460-A1 | TOPICAL FORMULATION | FQUBED, INC. | 2011-02-03 | — | — | US | disclosed |
| US-7879802-B2 | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders | SYNERGY PHARMACEUTICALS INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20110021419-A1 | Methods and Compositions for the Treatment of Heart Failure and Other Disorders | Ironwood Pharmaceuticals Inc. | 2011-01-27 | — | — | US | disclosed |
| EP-1849795-B1 | 1-SUBSTITUTED-7-( -D-GLYCOPYRANOSYLOXY)(AZA)INDOLE COMPOUND AND PHARMACEUTICAL CONTAINING THE SAME | KISSEI PHARMACEUTICAL (JP) | 2011-01-26 | — | — | EP | disclosed |
| EP-1151749-B1 | SHEET-FORM ADHESIVE PREPARATION | HISAMITSU PHARMACEUTICAL CO (JP) | 2011-01-19 | — | — | EP | disclosed |
| US-7871998-B2 | Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity | ASTRAZENECA AB (SE) | 2011-01-18 | — | — | US | disclosed |
| US-7862807-B2 | Dendrimers as molecular translocators | UNIVERSITY OF CALIFORNIA, SAN DIEGO (US) | 2011-01-04 | — | — | US | disclosed |
| US-7863265-B2 | 2-azetidinone derivatives and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia | ASTRAZENECA AB (SE) | 2011-01-04 | — | — | US | disclosed |
| WO-2010141470-A2 | PROCESS FOR FORMING FILMS, FIBERS, AND BEADS FROM CHITINOUS BIOMASS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2010-12-09 | — | — | WO | disclosed |
| US-7842684-B2 | 2-azetidinone derivatives such as N-({4-[(2R,3R)-3-{[(2R)-2-(4-fluorophenyl)-2-hydroxyethyl]thio}-1-(4-{3-[(methylsulfonyl)amino]prop-1-yn-1-yl}phenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-3-cyclohexyl-D-alanine, used for the treatment of hyperlipemia | ASTRAZENECA AB (SE) | 2010-11-30 | — | — | US | disclosed |
| US-20100286160-A1 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | INTERVET INC. | 2010-11-11 | — | — | US | disclosed |
| WO-2010120817-A2 | NANOCHANNELED DEVICE AND RELATED METHODS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-10-21 | — | — | WO | disclosed |
| US-20100249144-A1 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | INTERVET INTERNATIONAL B.V. (NL) | 2010-09-30 | — | — | US | disclosed |
| US-20100227847-A1 | Non-Anilinic Derivatives Of Isothiazol-3(2H)-one 1,1-Dioxides As Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2010-09-09 | — | — | US | disclosed |
| EP-1364958-B1 | GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND MEDICINAL USE THEREOF | KISSEI PHARMACEUTICAL (JP) | 2010-09-08 | — | — | EP | disclosed |
| US-20100216759-A1 | Novel 2-Azetidinone Derivatives And Their Use As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemia | ASTRAZENECA AB (SE) | 2010-08-26 | — | — | US | disclosed |
| US-20100197564-A1 | DIARYL MORPHOLINES AS CB1 MODULATORS | SCHERING CORPORATION | 2010-08-05 | — | — | US | disclosed |
| CN-101796033-A | As CB 1The piperazine of the replacement of antagonist | SCHERING CORP | 2010-08-04 | — | — | CN | disclosed |
| CN-101790521-A | Substituted-piperazinyl as the CB1 antagonist | INTERVET INT BV | 2010-07-28 | — | — | CN | disclosed |
| WO-2010078300-A1 | DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2010-07-08 | — | — | WO | disclosed |
| CN-101772513-A | Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and other diseases | SYNERGY PHARMACEUTICALS INC | 2010-07-07 | — | — | CN | disclosed |
| US-7749972-B2 | 1-substituted-7-(β-D-glycopyranosyloxy)(aza)indole compound and pharmaceutical containing the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-07-06 | — | — | US | disclosed |
| US-7750145-B2 | 1-substituted-3-β-D-glucopyranosylated nitrogenous hetero-cyclic compounds and medicines containing the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-07-06 | — | — | US | disclosed |
| US-20100168075-A1 | Novel 2-Azetidinone Derivatives As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemic Conditions | ASTRAZENECA AB (SE) | 2010-07-01 | — | — | US | disclosed |
| US-20100168039-A1 | Novel 2-Azetidinone Derivatives As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemic Conditions | ASTRAZENECA AB (SE) | 2010-07-01 | — | — | US | disclosed |
| US-7741289-B2 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2010-06-22 | — | — | US | disclosed |
| US-20100152699-A1 | Nanochanneled Device and Related Methods | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152118-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA, ATHEROSCLEROSIS, CORONARY HEART DISEASE, GALLSTONE, OBESITY AND OTHER CARDIOVASCULAR DISEASES | SYNERGY PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152156-A1 | 2-Azetidinone Derivatives For The Treatment Of Hyperlipidaemic Diseases | ASTRAZENECA AB (SE) | 2010-06-17 | — | — | US | disclosed |
| US-7732596-B2 | Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-06-08 | — | — | US | disclosed |
| US-7732413-B2 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2010-06-08 | — | — | US | disclosed |
| US-20100137273-A1 | Novel 2-Azetidinone Derivatives As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemic Conditions | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | US | disclosed |
| EP-1544208-B1 | PYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF | KISSEI PHARMACEUTICAL (JP) | 2010-05-26 | — | — | EP | disclosed |
| US-7723333-B2 | Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2010-05-25 | — | — | US | disclosed |
| WO-2010056986-A2 | NANOCHANNELED DEVICE AND RELATED METHODS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20100120694-A1 | Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders | SYNERGY PHARMACEUTICALS, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100099657-A2 | Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity | ASTRAZENECA AB (SE) | 2010-04-22 | — | — | US | disclosed |
| US-7700597-B2 | Substituted piperazines as CB1 antagonists | SCHERING CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| US-20100093635-A1 | Agonists of Guanylate Cyclase UseFul For The Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders | SYNERGY PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| EP-2170930-A2 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS | Synergy Pharmaceuticals Inc. (US) | 2010-04-07 | — | — | EP | disclosed |
| EP-2170846-A2 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | Intervet International BV (NL) | 2010-04-07 | — | — | EP | disclosed |
| EP-2170845-A1 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | Intervet International BV (NL) | 2010-04-07 | — | — | EP | disclosed |
| EP-2170847-A2 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | Intervet International BV (NL) | 2010-04-07 | — | — | EP | disclosed |
| US-20100069306-A1 | Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders | SYNERGY PHARMACEUTICALS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100048530-A1 | New 2-Azetidinone Derivatives As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemic Conditions | ASTRAZENECA AB (SE) | 2010-02-25 | — | — | US | disclosed |
| US-20100048529-A1 | New 2-Azetidinone Derivatives Useful In The Treatment Of Hyperlipidaemic Conditions | ASTRAZENECA AB (SE) | 2010-02-25 | — | — | US | disclosed |
| CN-101657471-A | Bicyclic compounds and their use as antidiabetics | SMITHKLINE BEECHAM CORP US | 2010-02-24 | — | — | CN | disclosed |
| EP-2152266-A1 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS ASSOCIATED WITH SALT OR FLUID RETENTION | Ironwood Pharmaceuticals, Inc. (US) | 2010-02-17 | — | — | EP | disclosed |
| WO-2010014593-A1 | CHEMICAL COMPOUNDS AND USES | SMITHKLINE BEECHAM CORPORATION (US) | 2010-02-04 | — | — | WO | disclosed |
| US-20100029919-A1 | PYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF AND INTERMEDIATE IN PRODUCING THE SAME | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100029650-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SMITH KLINE BEECHAM CORPORATION a corporation | 2010-02-04 | — | — | US | disclosed |
| US-20100029607-A1 | Substituted Piperazines as CB1 Antagonists | SCHERING CORPORATION | 2010-02-04 | — | — | US | disclosed |
| US-7655632-B2 | Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-02-02 | — | — | US | disclosed |
| US-7655633-B2 | Beta-D-Glucopyranosyloxy)-3-(3-fluoro-4-methylbenzyl)-4,6-dimethylpyridine; sodium glucose co-transporter 2 (SGLT2) inhibitors; excellent hypoglycemic effect by excreting excess glucose into the urine through preventing the reabsorption of glucose at the kidney; antidiabetic agents; hyperglycemia | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-02-02 | — | — | US | disclosed |
| US-20100016321-A1 | DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATOR | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | disclosed |
| WO-2010009319-A2 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL, INFLAMMATION, CANCER AND OTHER DISORDERS | SYNERGY PHARMACEUTICALS INC. (US) | 2010-01-21 | — | — | WO | disclosed |
| US-20090318477-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2009-12-24 | — | — | US | disclosed |
| CN-100571701-C | Therapeutic articles for treating beta amyloid related diseases | NEUROCHEM INTERNAT LTD (CH) | 2009-12-23 | — | — | CN | disclosed |
| US-7635684-B2 | treatment of disease associated with hyperglycemia: diabetes, impaired glucose tolerance, impaired fasting glycemia, diabetic complications or obesity; e.g. -[(4-{3-[N-(Carbamoylmethyl)-N-(methanesulfonyl)amino]-propoxy}-2-methylphenyl)methyl]-3-( beta -D-glucopyranosyloxy)-5-isopropyl-1H-pyrazole | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-12-22 | — | — | US | disclosed |
| US-20090311249-A1 | Capecitabine Combination Therapy | ARIAD PHARMACEUTICALS, INC. | 2009-12-17 | — | — | US | disclosed |
| WO-2009149279-A2 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS | SYNERGY PHARMACEUTICALS INC. (US) | 2009-12-10 | — | — | WO | disclosed |
| WO-2009148581-A1 | BIOCOMPATIBLE OLIGOMER-POLYMER COMPOSITIONS | QLT USA, INC. (US) | 2009-12-10 | — | — | WO | disclosed |
| US-20090305993-A1 | METHODS AND COMPOSITION FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| EP-2129683-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEART FAILURE AND OTHER DISORDERS | Ironwood Pharmaceuticals, Inc. (US) | 2009-12-09 | — | — | EP | disclosed |
| US-7625620-B2 | Sheet-type patch | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2009-12-01 | — | — | US | disclosed |
| WO-2009143367-A2 | EGF-A DOMAIN-MEDIATED MODULATION OF PCSK9 | SCHERING CORPORATION (US) | 2009-11-26 | — | — | WO | disclosed |
| US-7612058-B2 | Methods for inhibiting sterol absorption | SCHERING CORPORATION (US) | 2009-11-03 | — | — | US | disclosed |
| US-20090253634-A1 | Methods and Compositions for the Treatment of Gastrointestinal Disorders | MICROBIA, INC. (US) | 2009-10-08 | — | — | US | disclosed |
| EP-2094683-A2 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SmithKline Beecham Corporation (US) | 2009-09-02 | — | — | EP | disclosed |
| US-7582629-B2 | Derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2009-09-01 | — | — | US | disclosed |
| CN-101511429-A | Indulines derivatives and gpr119 agonists | SMITHKLINE BEECHAM CORP (US) | 2009-08-19 | — | — | CN | disclosed |
| US-7576064-B2 | Pyrazole derivative, drug composition containing the same and production intermediate therefor | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-08-18 | — | — | US | disclosed |
| US-7576063-B2 | Pyrazole derivative, medicinal composition containing the same, medicinal use thereof and intermediate in producing the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-08-18 | — | — | US | disclosed |
| US-20090203633-A1 | PYRAZOLE DERIVATIVES, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF | KISSEI PHARMACEUTICAL CO., LTD (JP) | 2009-08-13 | — | — | US | disclosed |
| CN-100522159-C | Use of substituted azetidinone compounds for the treatment of sitosterolemia | SCHERING CORP (US) | 2009-08-05 | — | — | CN | disclosed |
| US-20090192083-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | IRONWOOD PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
| US-7566699-B2 | Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-07-28 | — | — | US | disclosed |
| US-20090186834-A1 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | MICROBIA, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| CN-101479240-A | Diphenylazetidinone derivates possessing cholesterol absortion inhibitor activity | ASTRAZENECA AB (SE) | 2009-07-08 | — | — | CN | disclosed |
| US-7541341-B2 | Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| EP-1354888-B1 | GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND USE THEREOF IN MEDICINES | KISSEI PHARMACEUTICAL (JP) | 2009-05-20 | — | — | EP | disclosed |
| US-20090105208-A1 | Substituted Piperazines as CB1 Antagonists | SCHERING CORPORATION | 2009-04-23 | — | — | US | disclosed |
| US-20090093419-A1 | GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND USE THEREOF IN MEDICINES | KISSEI PHARMACEUTICAL CO. LTD. (JP) | 2009-04-09 | — | — | US | disclosed |
| EP-2043744-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2009-04-08 | — | — | EP | disclosed |
| US-20090074738-A1 | 1-SUBSTITUTED-3-BETA-D-GLUCOPYRANOSYLATED NITROGENOUS HETERO-CYCLIC COMPOUNDS AND MEDICINES CONTAINING THE SAME | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-03-19 | — | — | US | disclosed |
| US-20090069285-A1 | Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitor Activity | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| EP-2032168-A1 | CAPECITABINE COMBINATION THERAPY | ARIAD GENE THERAPEUTICS, INC. (US) | 2009-03-11 | — | — | EP | disclosed |
| US-20090054356-A1 | 1-SUBSTITUTED-7-(B-D-GLYCOPYRANOSYLOXY)(AZA)INDOLE COMPOUND AND PHARMACEUTICAL CONTAINING THE SAME | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
| US-20090054319-A1 | Methods and Compositions for the Treatment of Hypertension and Gastrointestinal Disorders | MICROBIA, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| EP-1853295-A4 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | MICROBIA INC (US) | 2009-02-25 | — | — | EP | disclosed |
| US-20090048175-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS | SYNERGY PHARMACEUTICALS, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090029945-A2 | Non-Anilinic Derivatives of Isothiazol-3(2H)-Thione 1,1-Dioxides As Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| EP-2013165-A1 | DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSOR TION INHIBITOR ACTIVIT. | Astra Zeneca AB (SE) | 2009-01-14 | — | — | EP | disclosed |
| WO-2009005671-A2 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | SCHERING CORPORATION (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009005645-A1 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | SCHERING CORPORATION (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009005646-A2 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | SCHERING CORPORATION (US) | 2009-01-08 | — | — | WO | disclosed |
| US-20090005353-A1 | Non-Anilinic Derivatives of Isothiazol-3(2H)-one 1,1-Dioxides as Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2009-01-01 | — | — | US | disclosed |
| US-20090005321-A1 | Phenylazetidinone Derivatives | MICROBIA, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| EP-1364957-B1 | GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND MEDICINAL USE THEREOF | KISSEI PHARMACEUTICAL (JP) | 2008-12-31 | — | — | EP | disclosed |
| US-7470678-B2 | Diphenylazetidinone derivatives for treating disorders of the lipid metabolism | ASTRAZENECA AB (SE) | 2008-12-30 | — | — | US | disclosed |
| US-20080319017-A2 | Non-Anilinic Derivatives of Isothiazol-3(2H)-Thione 1,1-Dioxides As Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20080319092-A1 | Transdermal Drug Delivery Formulation | NUVO RESEARCH INC. (CA) | 2008-12-25 | — | — | US | disclosed |
| EP-1601669-B1 | SUBSTITUTED AZETIDINONE COMPOUNDS, FORMULATIONS AND USES THEREOF FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | SCHERING CORP (US) | 2008-12-24 | — | — | EP | disclosed |
| US-20080312153-A1 | PYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
| CN-101326275-A | Multifunctional ionic liquid composition | UNIV ALABAMA (US) | 2008-12-17 | — | — | CN | disclosed |
| US-7465713-B2 | Glucopyranosyloxypyrazole derivatives and use thereof in medicines | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-12-16 | — | — | US | disclosed |
| WO-2008151257-A2 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS | SYNERGY PHARMACEUTICALS INC. (US) | 2008-12-11 | — | — | WO | disclosed |
| EP-1996218-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | Ironwood Pharmaceuticals, Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| US-7459442-B2 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2008-12-02 | — | — | US | disclosed |
| WO-2008137318-A1 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS ASSOCIATED WITH SALT OR FLUID RETENTION | IRONWOOD PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008130616-A2 | DIARYL MORPHOLINES AS CB1 MODULATORS | SCHERING CORPORATION (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20080261942-A1 | COMBINATIONS OF BILE ACID SEQUESTRANT(S) AND STEROL ABSORPTION INHIBITOR(S) AND TREATMENTS FOR VASCULAR INDICATIONS | SCHERING CORPORATION (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080255122-A1 | Derivatives of Isothiazol-3(2H)-One 1,1-Dioxides as Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
| EP-1427409-B1 | METHODS FOR TREATING OR PREVENTING VASCULAR INFLAMMATION USING STEROL ABSORPTION INHIBITOR(S) | SCHERING CORP (US) | 2008-10-15 | — | — | EP | disclosed |
| EP-1973877-A2 | CANNIBINOID RECEPTOR MODULATORS | SCHERING CORPORATION (US) | 2008-10-01 | — | — | EP | disclosed |
| US-7429568-B2 | Antidiabetic agents; human SGLT2 (sodium ion / glucose cotransporter 2) inhibitors; hyperglycemia, obesity; 3-(6-O-ethoxycarbonyl- beta -D-glucopyranosyloxy)-4-[(4-isopropoxyphenyl)methyl]-1-isopropyl-5-methylpyrazole | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-09-30 | — | — | US | disclosed |
| US-20080234248-A1 | Substituted Azetidinone Compounds, Processes for Preparing the Same, Formulations and Uses Thereof | SCHERING CORPORATION (US) | 2008-09-25 | — | — | US | disclosed |
| US-20080221020-A1 | Dendrimers as Molecular Translocators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-09-11 | — | — | US | disclosed |
| WO-2008106429-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEART FAILURE AND OTHER DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| US-20080207585-A1 | Substituted Azetidinone Compounds, Processes for Preparing the Same, Formulations and Uses Thereof | SCHERING CORPORATION (US) | 2008-08-28 | — | — | US | disclosed |
| EP-1601668-B1 | SUBSTITUTED AZETIDINONE COMPOUNDS, FORMULATIONS AND USES THEREOF FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | SCHERING CORP (US) | 2008-08-27 | — | — | EP | disclosed |
| US-7417039-B2 | Use of substituted azetidinone compounds for the treatment of sitosterolemia | SCHERING CORPORATION (US) | 2008-08-26 | — | — | US | disclosed |
| US-20080200446-A1 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080194494-A1 | 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia | MICROBIA, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080188426-A1 | NITROGENOUS FUSED-RING DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE DERIVATIVES, AND USE THEREOF AS DRUGS | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-08-07 | — | — | US | disclosed |
| EP-1940441-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | Microbia, Inc. (US) | 2008-07-09 | — | — | EP | disclosed |
| US-7393838-B2 | Glucopyranosyloxypyrazole derivatives and use thereof in medicines | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-07-01 | — | — | US | disclosed |
| EP-1931760-A2 | MULTI-FUNCTIONAL IONIC LIQUID COMPOSITIONS | The University of Alabama (US) | 2008-06-18 | — | — | EP | disclosed |
| WO-2008070692-A2 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | WO | disclosed |
| US-20080139484-A1 | 1(Beta-D-Glycopyranosyl)-3-Substituted Nitrogenous Heterocyclic Compound, Medicinal Composition Containing the Same, and Medicinal Use Thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-06-12 | — | — | US | disclosed |
| US-20080139616-A1 | Atherosclerosis; inflammatory diseases, Alzheimer's disease, dyslipidemia, metabolic syndrome; 2-isopropyl-5-phenyl-4-[(4-phenylbutyl)amino]isothiazole-3(2H)-thione 1,1-dioxide for example | ASTRAZENECA AB (SE) | 2008-06-12 | — | — | US | disclosed |
| US-20080125396-A1 | Derivatives of Isothiazol-3(2H)-Thione 1,1-Dioxides as Liver X Receptor Modulators | ATRAZENECA AB (SE) | 2008-05-29 | — | — | US | disclosed |
| US-7378518-B2 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2008-05-27 | — | — | US | disclosed |
| US-7375113-B2 | Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-05-20 | — | — | US | disclosed |
| US-7375087-B2 | Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-05-20 | — | — | US | disclosed |
| EP-1918000-A2 | Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions | SCHERING CORPORATION (US) | 2008-05-07 | — | — | EP | disclosed |
| US-7368563-B2 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368562-B2 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| EP-1911462-A2 | Compositions comprising a sterol absorption inhibitor | SCHERING CORPORATION (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1909772-A1 | TRANSDERMAL DRUG DELIVERY FORMULATION | Nuvo Research Inc. (CA) | 2008-04-16 | — | — | EP | disclosed |
| WO-2008039829-A2 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2008-04-03 | — | — | WO | disclosed |
| US-20080064676-A1 | Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| EP-1896457-A1 | NEW 2-AZETIDINONE DERIVATIVES USEFUL IN THE TREATMENT OF HYPERLIPIDAEMIC CONDITIONS | AstraZeneca AB (SE) | 2008-03-12 | — | — | EP | disclosed |
| EP-1896458-A1 | NEW 2-AZETIDINONE DERIVATIVES AS CHOLESTEROL ABSORPTION INHIBITORS FOR THE TREATMENT OF HYPERLIPIDAEMIC CONDITIONS | AstraZeneca AB (SE) | 2008-03-12 | — | — | EP | disclosed |
| EP-1896409-A1 | NOVEL 2-AZETIDINONE DERIVATIVES AS CHOLESTEROL ABSORPTION INHIBITORS USEFUL FOR THE TREATMENT OF HYPERLIPIDAEMIC CONDITIONS | AstraZeneca AB (SE) | 2008-03-12 | — | — | EP | disclosed |
| EP-1896408-A1 | NEW 2-AZETIDINONE DERIVATIVES FOR THE TREATMENT OF HYPERLIPIDAEMIC DISEASES | AstraZeneca AB (SE) | 2008-03-12 | — | — | EP | disclosed |
| EP-1896410-A1 | NOVEL 2-AZETIDINONE DERIVATIVES AS CHOLESTEROL ABSORPTION INHIBITORS FOR THE TREATMENT OF HYPERLIPIDAEMIC CONDITIONS | AstraZeneca AB (SE) | 2008-03-12 | — | — | EP | disclosed |
| EP-1896407-A1 | NOVEL 2-AZETIDINONE DERIVATIVES AND THEIR USE AS CHOLESTEROL ABSORPTION INHIBITORS FOR THE TREATMENT OF HYPERLIPIDAEMIA | AstraZeneca AB (SE) | 2008-03-12 | — | — | EP | disclosed |
| EP-1896459-A1 | NOVEL 2-AZETIDINONE DERIVATIVES AS CHOLESTEROL ABSORPTION INHIBITORS FOR THE TREATMENT OF HYPERLIPIDAEMIC CONDITIONS | AstraZeneca AB (SE) | 2008-03-12 | — | — | EP | disclosed |
| US-20080058306-A1 | Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitors(s) and treatments for vascular indications | DAVIS HARRY R | 2008-03-06 | — | — | US | disclosed |
| EP-1885694-A2 | 4-BIARYLYL-1-PHENYLAZETIDIN-2-ONES | Microbia, Inc. (US) | 2008-02-13 | — | — | EP | disclosed |
| EP-1879860-A2 | 1,4-DIPHENYL-3-HYDROXYALKYL-2-AZETIDINONE DERIVATIVES FOR TREATING HYPERCHOLESTROLEMIA | Microbia Inc. (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2008008895-A1 | GPR119 AGONISTS FOR THE TREATMENT OF DIABETES AND RELATED DISORDERS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008008887-A2 | GPR119 AGONISTS FOR TREATING METABOLIC DISORDERS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-17 | — | — | WO | disclosed |
| EP-1877067-A1 | 4-BIARYLYL-1-PHENYLAZETIDIN-2-ONE GLUCURONIDE DERIVATIVES FOR HYPERCHOLESTEROLEMIA | Microbia, Inc. (US) | 2008-01-16 | — | — | EP | disclosed |
| EP-1877373-A2 | BIPHENYLAZETIDINONE CHOLESTEROL ABSORPTION INHIBITORS | Microbia, Inc. (US) | 2008-01-16 | — | — | EP | disclosed |
| CN-101103969-A | Therapeutic formulations for the treatment of beta-amyloid related diseases | NEUROCHEM INTERNAT LTD (CH) | 2008-01-16 | — | — | CN | disclosed |
| WO-2008002971-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | MICROBIA, INC. (US) | 2008-01-03 | — | — | WO | disclosed |
| EP-1353694-B1 | COMBINATIONS OF EZETIMIBE WITH ASPIRINE FOR TREATING VASCULAR CONDITIONS | SCHERING CORP (US) | 2007-12-19 | — | — | EP | disclosed |
| WO-2007143212-A1 | CAPECITABINE COMBINATION THERAPY | ARIAD GENE THERAPEUTICS, INC. (US) | 2007-12-13 | — | — | WO | disclosed |
| EP-1864680-A2 | Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications | SCHERING CORPORATION (US) | 2007-12-12 | — | — | EP | disclosed |
| EP-1859796-A2 | TREATMENT OF XANTHOMA WITH AZETIDINONE DERIVATIVES AS STEROL ABSORPTION INHIBITORS | SCHERING CORPORATION (US) | 2007-11-28 | — | — | EP | disclosed |
| US-20070269379-A1 | Penetration Enhancer Combinations for Transdermal Delivery | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2007-11-22 | — | — | US | disclosed |
| EP-1853295-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | Microbia, Inc. (US) | 2007-11-14 | — | — | EP | disclosed |
| US-7294618-B2 | Glucopyranosyloxypyrazole derivatives and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-11-13 | — | — | US | disclosed |
| WO-2007126358-A1 | DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSOR TION INHIBITOR ACTIVIT. | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | WO | disclosed |
| EP-1851197-A2 | PHENYLAZETIDINONE DERIVATIVES | Microbia, Inc. (US) | 2007-11-07 | — | — | EP | disclosed |
| WO-2007123949-A2 | CANNABINOID RECEPTOR MODULATORS | SCHERING CORPORATION (US) | 2007-11-01 | — | — | WO | disclosed |
| EP-1849795-A1 | 1-SUBSTITUTED-7-( -D-GLYCOPYRANOSYLOXY)(AZA)INDOLE COMPOUND AND PHARMACEUTICAL CONTAINING THE SAME | Kissei Pharmaceutical Co., Ltd. (JP) | 2007-10-31 | — | — | EP | disclosed |
| EP-1841460-A2 | THERAPEUTIC FORMULATIONS FOR THE TREATMENT OF BETA-AMYLOID RELATED DISEASES | Neurochem (International) Limited (CH) | 2007-10-10 | — | — | EP | disclosed |
| EP-1838687-A1 | NON-ANILINIC DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2007-10-03 | — | — | EP | disclosed |
| EP-1838685-A1 | DERIVATIVES OF ISOTHIAZOL-3 (2H)-THIONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2007-10-03 | — | — | EP | disclosed |
| EP-1838686-A1 | DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2007-10-03 | — | — | EP | disclosed |
| EP-1838684-A1 | NON-ANILINIC DERIVATIVES OF ISOTHIAZOL-3(2H)-THIONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2007-10-03 | — | — | EP | disclosed |
| EP-1413331-B1 | Combinations of the peroxisome proliferator-activated receptor (PPAR) activator fenofibrate with sterol absorption inhibitor ezetimibe for vascular indications | SCHERING CORP (US) | 2007-10-03 | — | — | EP | disclosed |
| US-7271153-B2 | Treating diseases associated with hyperglycemia such as diabetes; SGLT2 (sodium/glucose cotransporter 2) inhibitor; 3-(4-Ethylbenzyl)-2-(beta-D-glucopyranosyloxy)-4,6-dimethyl-pyridine for example | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-09-18 | — | — | US | disclosed |
| WO-2007101161-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| US-20070197628-A1 | Cannabinoid receptor modulators | INTERVET INTERNATIONAL B.V. (NL) | 2007-08-23 | — | — | US | disclosed |
| US-20070197450-A1 | Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. | 2007-08-23 | — | — | US | disclosed |
| US-20070197449-A1 | Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-08-23 | — | — | US | disclosed |
| EP-1819684-A1 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | SCHERING CORPORATION (US) | 2007-08-22 | — | — | EP | disclosed |
| CN-1332654-C | Patch preparation | HISAMITSU PHARMACEUTICAL CO (JP) | 2007-08-22 | — | — | CN | disclosed |
| US-20070191289-A1 | Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1363668-B1 | COMBINATIONS OF BILE ACID SEQUESTRANT(S) AND STEROL ABSORPTION INHIBITOR(S) AND TREATMENTS FOR VASCULAR INDICATIONS | SCHERING CORP (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20070185197-A1 | Phenol derivative, medicinal composition containing the same, and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-08-09 | — | — | US | disclosed |
| EP-1545462-A4 | DENDRIMERS AS MOLECULAR TRANSLOCATORS | UNIV CALIFORNIA (US) | 2007-08-08 | — | — | EP | disclosed |
| EP-1813611-A1 | 1-SUBSTITUTED-3- BETA-D-GLUCOPYRANOSYLATED NITROGENOUS HETERO- CYCLIC COMPOUNDS AND MEDICINES CONTAINING THE SAME | Kissei Pharmaceutical Co., Ltd. (JP) | 2007-08-01 | — | — | EP | disclosed |
| WO-2007084450-A2 | CANNIBINOID RECEPTOR MODULATORS | SCHERING CORPORATION (US) | 2007-07-26 | — | — | WO | disclosed |
| EP-1810693-A2 | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions | Shering Corporation (US) | 2007-07-25 | — | — | EP | disclosed |
| EP-1810971-A1 | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia | SCHERING CORPORATION (US) | 2007-07-25 | — | — | EP | disclosed |
| EP-1807070-A1 | COMBINATIONS OF SUBSTITUTED AZETIDINONES AND CB1 ANTAGONISTS | SCHERING CORPORATION (US) | 2007-07-18 | — | — | EP | disclosed |
| US-20070155676-A1 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155674-A1 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155675-A1 | Substituted azetidinone compunds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2007-07-05 | — | — | US | disclosed |
| EP-1803729-A1 | 1-( -D-GLYCOPYRANOSYL)-3-SUBSTITUTED NITROGENOUS HETEROCYCLIC COMPOUND, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2007-07-04 | — | — | EP | disclosed |
| US-7235543-B2 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2007-06-26 | — | — | US | disclosed |
| US-20070142304-A1 | Diphenylazetidinone derivatives possessing chloesterol absorption inhibitory activity | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | US | disclosed |
| EP-1385548-B1 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | SCHERING CORP (US) | 2007-05-23 | — | — | EP | disclosed |
| EP-1785144-A2 | Combinations of bile acids sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications | Shering Corporation (US) | 2007-05-16 | — | — | EP | disclosed |
| US-7217697-B2 | Glucopyranosyloxypyrazole derivative medicinal composition containing the same medicinal use thereof and intermediate therefor | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-05-15 | — | — | US | disclosed |
| WO-2007049098-A2 | THERAPEUTIC FORMULATIONS FOR THE TREATMENT OF BETA-AMYLOID RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-05-03 | — | — | WO | disclosed |
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA | 2007-04-26 | — | — | US | disclosed |
| US-7208486-B2 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2007-04-24 | — | — | US | disclosed |
| WO-2007044693-A2 | MULTI-FUNCTIONAL IONIC LIQUID COMPOSITIONS | THE UNIVERSITY OF ALABAMA (US) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007022531-A9 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | MICROBIA INC (US) | 2007-04-19 | — | — | WO | disclosed |
| US-7199151-B2 | DHA-pharmaceutical agent conjugates of taxanes | LUITPOLD PHARMACEUTICALS, INC. (US) | 2007-04-03 | — | — | US | disclosed |
| CN-1934103-A | Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof | KISSEI PHARMACEUTICAL (JP) | 2007-03-21 | — | — | CN | disclosed |
| US-7192944-B2 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORP. (US) | 2007-03-20 | — | — | US | disclosed |
| US-20070060531-A1 | Pyrazole derivative, drug composition containing the same and production intermediate therefor | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-15 | — | — | US | disclosed |
| US-7189702-B2 | Glucopyranosyloxypyrazole derivatives and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-13 | — | — | US | disclosed |
| WO-2007022531-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | MICROBIA, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2007016766-A1 | TRANSDERMAL DRUG DELIVERY FORMULATION | NUVO RESEARCH INC. (CA) | 2007-02-15 | — | — | WO | disclosed |
| EP-1392287-B8 | Use of substituted azetidinone derivatives in the treatment of Alzheimer's disease | SCHERING CORP (US) | 2007-01-10 | — | — | EP | disclosed |
| WO-2006137782-A1 | NOVEL 2-AZETIDINONE DERIVATIVES AND THEIR USE AS CHOLESTEROL ABSORPTION INHIBITORS FOR THE TREATMENT OF HYPERLIPIDAEMIA | ASTRAZENECA AB (SE) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006137796-A1 | NOVEL 2-AZETIDINONE DERIVATIVES AS CHOLESTEROL ABSORPTION INHIBITORS FOR THE TREATMENT OF HYPERLIPIDAEMIC CONDITIONS | ASTRAZENECA AB (SE) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006137797-A1 | NOVEL 2-AZETIDINONE DERIVATIVES AS CHOLESTEROL ABSORPTION INHIBITORS FOR THE TREATMENT OF HYPERLIPIDAEMIC CONDITIONS | ASTRAZENECA AB (SE) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006137794-A1 | NEW2-AZETIDINONE DERIVATIVES FOR THE TREATMENT OF HYPERLIPIDAEMIC DISEASES | ASTRAZENECA AB (SE) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006137795-A1 | NOVEL 2-AZETIDINONE DERIVATIVES AS CHOLESTEROL ABSORPTION INHIBITORS USEFUL FOR THE TREATMENT OF HYPERLIPIDAEMIC CONDITIONS | ASTRAZENECA AB (SE) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006137792-A1 | NEW 2-AZETIDINONE DERIVATIVES USEFUL IN THE TREATMENT OF HYPERLIPIDAEMIC CONDITIONS | ASTRAZENECA AB (SE) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006137793-A1 | NEW 2-AZETIDINONE DERIVATIVES AS CHOLESTEROL ABSORPTION INHIBITORS FOR THE TREATMENT OF HYPERLIPIDAEMIC CONDITIONS | ASTRAZENECA AB (SE) | 2006-12-28 | — | — | WO | disclosed |
| US-20060287254-A1 | Use of substituted azetidinone compounds for the treatment of sitosterolemia | SCHERING CORPORATION | 2006-12-21 | — | — | US | disclosed |
| EP-1731524-A1 | PHENOL DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2006-12-13 | — | — | EP | disclosed |
| WO-2006124713-A2 | 4-BIARYLYL-1-PHENYLAZETIDIN-2-ONES | MICROBIA, INC. (US) | 2006-11-23 | — | — | WO | disclosed |
| EP-1724277-A1 | FUSED HETEROCYCLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2006-11-22 | — | — | EP | disclosed |
| EP-1724278-A1 | NITROGENOUS FUSED-RING DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE DERIVATIVES, AND USE THEREOF AS DRUGS | Kissei Pharmaceutical Co., Ltd. (JP) | 2006-11-22 | — | — | EP | disclosed |
| EP-1392287-B1 | USE OF AZETIDINONE SUBSTITUTED DERIVATIVES IN THE TREATMENT OF ALZHEIMER'S DISEASE | SCHERING CORP (US) | 2006-11-22 | — | — | EP | disclosed |
| EP-1429756-B1 | TREATMENT OF XANTHOMA WITH AZETIDINONE DERIVATIVES AS STEROL ABSORPTION INHIBITORS | SCHERING CORP (US) | 2006-11-22 | — | — | EP | disclosed |
| WO-2006122186-A2 | 1,4-DIPHENYL-3-HYDROXYALKYL-2-AZETIDINONE DERIVATIVES FOR TREATING HYPERCHOLESTROLEMIA | MICROBIA, INC. (US) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006121861-A2 | BIPHENYLAZETIDINONE CHOLESTEROL ABSORPTION INHIBITORS | MICROBIA, INC. (US) | 2006-11-16 | — | — | WO | disclosed |
| EP-1721904-A1 | FUSED HETEROCYCLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2006-11-15 | — | — | EP | disclosed |
| US-7132415-B2 | Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors | SCHERING CORPORATION (US) | 2006-11-07 | — | — | US | disclosed |
| WO-2006116499-A1 | 4-BIARYLYL-1-PHENYLAZETIDIN-2-ONE GLUCURONIDE DERIVATIVES FOR HYPERCHOLESTEROLEMIA | MICROBIA, INC. (US) | 2006-11-02 | — | — | WO | disclosed |
| US-20060247179-A1 | Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | US | disclosed |
| US-20060241121-A1 | Substituted piperazines as CB1 antagonists | MERCK SHARP & DOHME CORP. | 2006-10-26 | — | — | US | disclosed |
| US-20060216265-A1 | Dendrimers as molecular translocators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2006-09-28 | — | — | US | disclosed |
| WO-2006102674-A2 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | MICROBIA, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006102069-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION AND GASTROINTESTINAL DISORDERS | MICROBIA, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| US-20060217363-A1 | Methods and therapeutic combinations for the treatment of hypercholesterolemia and xanthoma using sterol absorption inhibitors | DAVIS HARRY R | 2006-09-28 | — | — | US | disclosed |
| EP-1699759-A1 | DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY | AstraZeneca AB (SE) | 2006-09-13 | — | — | EP | disclosed |
| EP-1699758-A1 | DIPHENYLAZETIDINONE DERIVATES PROCESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY | AstraZeneca AB (SE) | 2006-09-13 | — | — | EP | disclosed |
| US-20060199793-A1 | Sterol absorption inhibitor compounds | CHO WING-KEE P | 2006-09-07 | — | — | US | disclosed |
| WO-2006086653-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | MICROBIA, INC. (US) | 2006-08-17 | — | — | WO | disclosed |
| WO-2006086562-A2 | PHENYLAZETIDINONE DERIVATIVES | MICROBIA, INC. (US) | 2006-08-17 | — | — | WO | disclosed |
| US-7087579-B2 | Glucopyranosyloxypyrazole derivatives and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2006-08-08 | — | — | US | disclosed |
| US-7084123-B2 | Glucopyranosyloxypyrazole derivatives and use thereof in medicines | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2006-08-01 | — | — | US | disclosed |
| US-20060166899-A1 | Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1680189-A2 | COMBINATIONS OF LIPID MODULATING AGENTS AND SUBSTITUTED AZETIDINONES AND TREATMENTS FOR VASCULAR CONDITIONS | SCHERING CORPORATION (US) | 2006-07-19 | — | — | EP | disclosed |
| WO-2006073364-A1 | DERIVATIVES OF ISOTHIAZOL-3 (2H)-THIONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | disclosed |
| WO-2006073365-A1 | NON-ANILINIC DERIVATIVES OF ISOTHIAZOL-3(2H)-THIONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | disclosed |
| WO-2006073366-A1 | NON-ANILINIC DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | disclosed |
| WO-2006073363-A1 | DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | disclosed |
| US-7071181-B2 | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors | SCHERING CORPORATION (US) | 2006-07-04 | — | — | US | disclosed |
| US-20060142209-A1 | Glucopyranosyloxypyrazole derivatives and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. | 2006-06-29 | — | — | US | disclosed |
| EP-1355644-B1 | THE USE OF SUBSTITUTED AZETIDINONE COMPOUNDS FOR THE TREATMENT OF SITOSTEROLEMIA | SCHERING CORP (US) | 2006-06-28 | — | — | EP | disclosed |
| EP-1671650-A1 | Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications | Schering Corporation (US) | 2006-06-21 | — | — | EP | disclosed |
| US-7064242-B2 | Patch | HISAMITSU PHARMACEUTICALS CO., INC. (JP) | 2006-06-20 | — | — | US | disclosed |
| US-20060128635-A1 | Pyrazole derivative, medicinal composition containing the same, medicinal use thereof and intermediate in producing the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2006-06-15 | — | — | US | disclosed |
| WO-2006060461-A1 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | SCHERING CORPORATION (US) | 2006-06-08 | — | — | WO | disclosed |
| US-7056906-B2 | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women | SCHERING CORPORATION (US) | 2006-06-06 | — | — | US | disclosed |
| US-7053080-B2 | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors | SCHERING CORPORATION (US) | 2006-05-30 | — | — | US | disclosed |
| US-20060094667-A1 | Glucopyranosyloxypyrazole derivatives and use thereof in medicines | KISSEI PHARMACEUTICAL CO., LTD. | 2006-05-04 | — | — | US | disclosed |
| US-7030106-B2 | Sterol absorption inhibitor compositions | SCHERING CORPORATION (US) | 2006-04-18 | — | — | US | disclosed |
| WO-2006039334-A1 | COMBINATIONS OF SUBSTITUTED AZETIDONONES AND CB1 ANTAGONISTS | SCHERING CORPORATION (US) | 2006-04-13 | — | — | WO | disclosed |
| US-20060069080-A1 | Combinations of substituted azetidinones and CB1 antagonists | SCHERING CORPORATION | 2006-03-30 | — | — | US | disclosed |
| CN-1753675-A | Therapeutic articles for treating beta amyloid related diseases | NEUROCHEM INTERNAT LTD (CH) | 2006-03-29 | — | — | CN | disclosed |
| EP-1637539-A1 | PYRAZOLE DERIVATIVE, DRUG COMPOSITION CONTAINING THE SAME AND PRODUCTION INTERMEDIATE THEREFOR | Kissei Pharmaceutical Co., Ltd. (JP) | 2006-03-22 | — | — | EP | disclosed |
| US-20060035847-A1 | Glucopyranosyloxyprazole derivatives and use thereof in medicines | KISSEI PHARMACEUTICAL CO., LTD. | 2006-02-16 | — | — | US | disclosed |
| US-20060035840-A1 | Nitrogen-containing heterocyclic derivatives, medicinal compositions containing the same and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2006-02-16 | — | — | US | disclosed |
| US-20060030801-A1 | Patch | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2006-02-09 | — | — | US | disclosed |
| US-20060025352-A1 | Glucopyranosyloxypyrazole derivatives and use thereof in medicines | Kissei Pharmaceutical Co.,Ltd. | 2006-02-02 | — | — | US | disclosed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | disclosed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | disclosed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | disclosed |
| CN-1238363-C | Glucopyranosyloxypyrazole derivatives and use thereof in medicines | KISSEI PHARMACEUTICAL (JP) | 2006-01-25 | — | — | CN | disclosed |
| US-20060009399-A1 | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors | DAVIS HARRY R | 2006-01-12 | — | — | US | disclosed |
| EP-1609798-A1 | FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2005-12-28 | — | — | EP | disclosed |
| EP-1367060-B1 | GLUCOPYRANOSYLOXYBENZYLBENZENE DERIVATIVES AND MEDICINAL USE THEREOF | KISSEI PHARMACEUTICAL (JP) | 2005-12-28 | — | — | EP | disclosed |
| EP-1606287-A1 | SUBSTITUTED AZETIDINONE COMPOUNDS, FORMULATIONS AND USES THEREOF FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | SCHERING CORPORATION (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20050272669-A1 | Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2005-12-08 | — | — | US | disclosed |
| EP-1601668-A1 | SUBSTITUTED AZETIDINONE COMPOUNDS, FORMULATIONS AND USES THEREOF FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | SCHERING CORPORATION (US) | 2005-12-07 | — | — | EP | disclosed |
| EP-1601669-A1 | SUBSTITUTED AZETIDINONE COMPOUNDS, FORMULATIONS AND USES THEREOF FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | SCHERING CORPORATION (US) | 2005-12-07 | — | — | EP | disclosed |
| CN-1703250-A | Patch preparation | HISAMITSU PHARMACEUTICAL CO (JP) | 2005-11-30 | — | — | CN | disclosed |
| US-20050239766-A1 | Diphenylazetidinone derivatives for treating disorders of the lipid metabolism | ASTRAZENECA AB (SE) | 2005-10-27 | — | — | US | disclosed |
| EP-1585520-A1 | THERAPEUTIC FORMULATIONS FOR THE TREATMENT OF BETA-AMYLOID RELATED DISEASES | Neurochem (International) Limited (CH) | 2005-10-19 | — | — | EP | disclosed |
| EP-1577317-A1 | NITROGEN-CONTAINING HETEROCYCIC DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE SAME AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-6936268-B1 | Sheet-form adhesive preparation | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2005-08-30 | — | — | US | disclosed |
| US-20050181163-A1 | Sheet-type patch | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2005-08-18 | — | — | US | disclosed |
| US-20050153952-A1 | Administering 1-(4-fluorophenyl)-3(R)-[3(S)-(4-fluorophenyl)-3-hydroxypropyl)]-4(S)-[4-(phenylmethoxy)phenyl]-2-azetidinone; and peroxisome proliferator-activated receptor activator; obesity, antidiabetic agents | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2005-07-14 | — | — | US | disclosed |
| WO-2005061451-A1 | DIPHENYLAZETIDINONE DERIVATES PROCESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005061452-A1 | DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
| EP-1550668-A1 | PYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF AND INTERMEDIATE IN PRODUCING THE SAME | Kissei Pharmaceutical Co., Ltd. (JP) | 2005-07-06 | — | — | EP | disclosed |
| EP-1548024-A1 | PYRAZOLE DERIVATIVES, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2005-06-29 | — | — | EP | disclosed |
| EP-1545462-A2 | DENDRIMERS AS MOLECULAR TRANSLOCATORS | The Regents of the University of California (US) | 2005-06-29 | — | — | EP | disclosed |
| EP-1544208-A1 | PYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2005-06-22 | — | — | EP | disclosed |
| EP-1541175-A2 | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | Schering Corporation (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2005046797-A2 | COMBINATIONS OF LIPID MODULATING AGENTS AND SUBSTITUTED AZETIDINONES AND TREATMENTS FOR VASCULAR CONDITIONS | SCHERING CORPORATION (US) | 2005-05-26 | — | — | WO | disclosed |
| US-20050096307-A1 | Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions | SCHERING CORPORATION | 2005-05-05 | — | — | US | disclosed |
| US-20050080071-A1 | Treatment methods | DAVIS HARRY R (US) | 2005-04-14 | — | — | US | disclosed |
| EP-1521742-A1 | DIPHENYLAZETIDINONE DERIVATIVES FOR TREATING DISORDERS OF THE LIPID METABOLISM | AstraZeneca AB (SE) | 2005-04-13 | — | — | EP | disclosed |
| US-20050049203-A1 | Nitrogenous heterocyclic derivative, medicinal composition containing the same, medical use thereof, and intermediate therefor | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2005-03-03 | — | — | US | disclosed |
| US-20050031651-A1 | Administering a combination of an agent that treats an amyloid-P disease, neurodegeneration, or cellular toxicity; and said second agent is a therapeutic drug or nutritive supplement | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2005-02-10 | — | — | US | disclosed |
| WO-2005009510-A2 | PENETRATION ENHANCER COMBINATIONS FOR TRANSDERMAL DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-02-03 | — | — | WO | disclosed |
| CN-1556700-A | Methods of treating or preventing vasculitis using sterol absorption inhibitors | ���鹫˾ | 2004-12-22 | — | — | CN | disclosed |
| US-20040214811-A1 | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors | SCHERING CORPORATION | 2004-10-28 | — | — | US | disclosed |
| EP-1466628-A1 | DHA-pharmaceutical agent conjugates | Luitpold Pharmaceuticals, Inc. (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040198700-A1 | Administering to a patient an azetidinone compound containing at least 3 phenyl rings fo rprevention of a vascular condition, diabetes, obesity, stroke, lowering a concentration of a sterol or stanol in plasma of a mammal, preventing demyelination or treating Alzheimer's disease | SCHERING CORPORATION | 2004-10-07 | — | — | US | disclosed |
| WO-2004081004-A1 | SUBSTITUTED AZETIDINONE COMPOUNDS, FORMULATIONS AND USES THEREOF FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | SCHERING CORPORATION (US) | 2004-09-23 | — | — | WO | disclosed |
| WO-2004081002-A1 | SUBSTITUTED AZETIDINONE COMPOUNDS, FORMULATIONS AND USES THEREOF FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | SCHERING CORPORATION (US) | 2004-09-23 | — | — | WO | disclosed |
| WO-2004081003-A1 | SUBSTITUTED AZETIDINONE COMPOUNDS, FORMULATIONS AND USES THEREOF FOR THE TREATMENT OF HYPERCHOLETEROLEMIA | SCHERING CORPORATION (US) | 2004-09-23 | — | — | WO | disclosed |
| US-20040180861-A1 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION | 2004-09-16 | — | — | US | disclosed |
| US-20040180860-A1 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION | 2004-09-16 | — | — | US | disclosed |
| US-20040180949-A1 | conjugates of pharmaceutical agents and a highly lipphilic group, a C22 unbranched carbon chain; render the activity of these compounds selective for colon tissue, breast tissue and central nervous system tissue | PROTARGA, INC. | 2004-09-16 | — | — | US | disclosed |
| US-20040176308-A1 | Glucopyranosyloxypyrazole derivative medicinal composition containing the same medicinal use thereof and intermediate therefor | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2004-09-09 | — | — | US | disclosed |
| CN-1527707-A | The use of substituted azetidinone compounds for the treatment of sitosterolemia | ���鹫˾ | 2004-09-08 | — | — | CN | disclosed |
| US-20040156886-A1 | Sheet-like patch agent | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2004-08-12 | — | — | US | disclosed |
| US-20040138148-A1 | Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| WO-2004058258-A1 | THERAPEUTIC FORMULATIONS FOR THE TREATMENT OF BETA-AMYLOID RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2004-07-15 | — | — | WO | disclosed |
| US-20040132669-A1 | Human sodium glucose co-transporter 2 (SGLT2) inhibitors; hypoglycemic agents, antidiabetic agents; obesity; prodrugs | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
| EP-1429756-A2 | TREATMENT OF XANTHOMA WITH AZETIDINONE DERIVATIVES AS STEROL ABSORPTION INHIBITORS | SCHERING CORPORATION (US) | 2004-06-23 | — | — | EP | disclosed |
| US-20040116357-A1 | For prophylaxis and therapy of hyperglycemia such as diabetes, diabetic complications or obesity | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-17 | — | — | US | disclosed |
| EP-1427409-A1 | METHODS FOR TREATING OR PREVENTING VASCULAR INFLAMMATION USING STEROL ABSORPTION INHIBITOR(S) | SCHERING CORPORATION (US) | 2004-06-16 | — | — | EP | disclosed |
| US-20040106589-A1 | Fatty acid-pharmaceutical agent conjugates | PROTARGA PHARMACEUTICALS, INC. | 2004-06-03 | — | — | US | disclosed |
| US-20040097482-A1 | Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications | SCHERING CORPORATION | 2004-05-20 | — | — | US | disclosed |
| EP-1413331-A2 | Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) for vascular indications | SCHERING CORPORATION (US) | 2004-04-28 | — | — | EP | disclosed |
| CN-1492873-A | Glucopyranosyloxypyrazole derivatives and their use in medicaments | ����ҩƷ��ҵ��ʽ���� | 2004-04-28 | — | — | CN | disclosed |
| EP-1405859-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF AND INTERMEDIATE THEREFOR | Kissei Pharmaceutical Co., Ltd. (JP) | 2004-04-07 | — | — | EP | disclosed |
| US-20040063646-A1 | Glucopyranosyloxypyrazole derivatives and use thereof in medicines | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1400529-A1 | GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE THEREFOR | Kissei Pharmaceutical Co., Ltd. (JP) | 2004-03-24 | — | — | EP | disclosed |
| US-6710086-B1 | CHEMICALLY MODIFIED PHARMACOLOGICALLY ACTIVE AGENT IN CARRIER; REDUCE THE DAMAGE TO THE GASTROINTESTINAL TRACT | MEDINOX, INC. | 2004-03-23 | — | — | US | disclosed |
| EP-1392287-A2 | USE OF AZETIDINONE SUBSTITUTED DERIVATIVES IN THE TREATMENT OF ALZHEIMER'S DISEASE | SCHERING CORPORATION (US) | 2004-03-03 | — | — | EP | disclosed |
| EP-1385548-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | Schering Corporation (US) | 2004-02-04 | — | — | EP | disclosed |
| WO-2004009665-A2 | DENDRIMERS AS MOLECULAR TRANSLOCATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-01-29 | — | — | WO | disclosed |
| WO-2004009666-A2 | DENDRIMERS AS MOLECULAR TRANSLOCATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-01-29 | — | — | WO | disclosed |
| WO-2004005247-A1 | DIPHENYLAZETIDINONE DERIVATIVES FOR TREATING DISORDERS OF THE LIPID METABOLISM | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | disclosed |
| EP-1367060-A1 | GLUCOPYRANOSYLOXYBENZYLBENZENE DERIVATIVES AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2003-12-03 | — | — | EP | disclosed |
| EP-1364958-A1 | GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2003-11-26 | — | — | EP | disclosed |
| EP-1364957-A1 | GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2003-11-26 | — | — | EP | disclosed |
| EP-1363668-A2 | COMBINATIONS OF BILE ACID SEQUESTRANT(S) AND STEROL ABSORPTION INHIBITOR(S) AND TREATMENTS FOR VASCULAR INDICATIONS | Schering Corporation (US) | 2003-11-26 | — | — | EP | disclosed |
| US-6649591-B2 | Dithiocarbamates linked to the surface of a non-immunogenic, non-targeting macromolecule other than an antibody (e.g., albumin protein); treating cerebral stroke and other ischemia/reperfusion injury | MEDINOX, INC. | 2003-11-18 | — | — | US | disclosed |
| EP-1355644-A2 | THE USE OF SUBSTITUTED AZETIDINONE COMPOUNDS FOR THE TREATMENT OF SITOSTEROLEMIA | SCHERING CORPORATION (US) | 2003-10-29 | — | — | EP | disclosed |
| EP-1353695-A2 | COMBINATIONS OF NICOTINIC ACID AND DERIVATIVES THEREOF AND STEROL ABSORPTION INHIBITOR(S) AND TREATMENTS FOR VASCULAR INDICATIONS | Schering Corporation (US) | 2003-10-22 | — | — | EP | disclosed |
| EP-1354888-A1 | GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND USE THEREOF IN MEDICINES | Kissei Pharmaceutical Co., Ltd. (JP) | 2003-10-22 | — | — | EP | disclosed |
| EP-1353694-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH BLOOD MODIFIER(S) FOR TREATING VASCULAR CONDITIONS | Schering Corporation (US) | 2003-10-22 | — | — | EP | disclosed |
| EP-1353696-A2 | COMBINATIONS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) ACTIVATOR(S) AND STEROL ABSORPTION INHIBITOR(S) AND TREATMENTS FOR VASCULAR INDICATIONS | Schering Corporation (US) | 2003-10-22 | — | — | EP | disclosed |
| US-20030181495-A1 | Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor | MEDINOX, INC. | 2003-09-25 | — | — | US | disclosed |
| US-6602902-B2 | Targeting a pharmaceutical agent to a noncentral nervous system tissue by administering a covalent conjugate of the drug and cis-docosahexanoic acid | PROTARGA, INC. | 2003-08-05 | — | — | US | disclosed |
| US-6596770-B2 | Disulfide derivative of a dithiocarbamate is coadministered with an agent that inactivates (or inhibits the production of)the species that induce the expression of nitric oxide synthase | MEDINOX, INC. | 2003-07-22 | — | — | US | disclosed |
| EP-1089723-A4 | THERAPEUTIC METHODS EMPLOYING DISULFIDE DERIVATIVES OF DITHIOCARBAMATES AND COMPOSITIONS USEFUL THEREFOR | MEDINOX INC (US) | 2003-07-16 | — | — | EP | disclosed |
| US-6589991-B1 | Treating diseases associated with nuclear factor kappa B pathway; nitric oxide synthase inhibitors, antiinflammatory agents | MEDINOX, INC. | 2003-07-08 | — | — | US | disclosed |
| US-20030119808-A1 | Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects | SCHERING CORPORATION | 2003-06-26 | — | — | US | disclosed |
| US-20030119757-A1 | Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s) | SCHERING CORPORATION | 2003-06-26 | — | — | US | disclosed |
| US-20030119428-A1 | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors | SCHERING CORPORATION | 2003-06-26 | — | — | US | disclosed |
| US-20030119796-A1 | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women | SCHERING CORPORATION | 2003-06-26 | — | — | US | disclosed |
| US-20030119809-A1 | Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors | SCHERING CORPORATION | 2003-06-26 | — | — | US | disclosed |
| US-6576636-B2 | Treating a noncentral nervous system by administering a covalent conjugate of a C8-26, unbranched, naturally occurring fatty acid and a drug, provided the drug is not an adenosine receptor agonist/antagonist; anticarcinogenics | PROTARGA, INC. | 2003-06-10 | — | — | US | disclosed |
| US-20030087840-A1 | Conjugates of dithiocarbamates with pharmacologically active agents and uses therefor | MEDINOX, INC. | 2003-05-08 | — | — | US | disclosed |
| US-20030069221-A1 | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | SCHERING CORPORATION | 2003-04-10 | — | — | US | disclosed |
| WO-2003026643-A2 | TREATMENT OF XANTHOMA WITH AZETIDINONE DERIVATIVES AS STEROL ABSORPTION INHIBITORS | SCHERING CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| WO-2003026644-A1 | METHODS FOR TREATING OR PREVENTING VASCULAR INFLAMMATION USING STEROL ABSORPTION INHIBITOR(S) | SCHERING CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| US-20030059471-A1 | Oral delivery formulation | COMPTON BRUCE JON (US) | 2003-03-27 | — | — | US | disclosed |
| US-20030053981-A1 | Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications | SCHERING CORPORATION | 2003-03-20 | — | — | US | disclosed |
| WO-2002058733-A9 | COMBINATIONS OF BILE ACID SEQUESTRANT(S) AND STEROL ABSORPTION INHIBITOR(S) AND TREATMENTS FOR VASCULAR INDICATIONS | SCHERING CORP (US) | 2003-03-06 | — | — | WO | disclosed |
| US-20030013699-A1 | Methods for treating alzheimer's disease and/or regulating levels of amyloid beta peptides in a subject | SCHERING CORPORATION | 2003-01-16 | — | — | US | disclosed |
| US-20020192203-A1 | Sterol absorption inhibitor compositions | U.S. BANK, NATIONAL ASSOCIATION , AS COLLATERAL AGENT | 2002-12-19 | — | — | US | disclosed |
| US-20020183305-A1 | Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications | SCHERING CORPORATION | 2002-12-05 | — | — | US | disclosed |
| WO-2002096415-A2 | USE OF AZETIDINONE SUBSTITUTED DERIVATIVES IN THE TREATMENT OF ALZHEIMER'S DISEASE | SCHERING CORPORATION (US) | 2002-12-05 | — | — | WO | disclosed |
| US-20020169134-A1 | Use of substituted azetidinone compounds for the treatment of sitosterolemia | SCHERING CORPORATION | 2002-11-14 | — | — | US | disclosed |
| US-20020151536-A1 | Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications | SCHERING CORPORATION | 2002-10-17 | — | — | US | disclosed |
| US-20020151540-A1 | Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor | MEDINOX, INC. | 2002-10-17 | — | — | US | disclosed |
| US-20020147184-A1 | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions | SCHERING CORPORATION | 2002-10-10 | — | — | US | disclosed |
| WO-2002058732-A2 | COMBINATIONS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) ACTIVATOR(S) AND STEROL ABSORPTION INHIBITOR(S) AND TREATMENTS FOR VASCULAR INDICATIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002058685-A2 | COMBINATIONS OF NICOTINIC ACID AND DERIVATIVES THEREOF AND STEROL ABSORPTION INHIBITOR(S) AND TREATMENTS FOR VASCULAR INDICATIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002058731-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002058733-A2 | COMBINATIONS OF BILE ACID SEQUESTRANT(S) AND STEROL ABSORPTION INHIBITOR(S) AND TREATMENTS FOR VASCULAR INDICATIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002058734-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH BLOOD MODIFIER(S) FOR TREATING VASCULAR CONDITIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002058696-A2 | THE USE OF SUBSTITUTED AZETIDINONE COMPOUNDS FOR THE TREATMENT OF SITOSTEROLEMIA | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
| US-6407135-B1 | NITRIC OXIDE SCAVENGER COVALENTLY BONDED TO NON-STEROIDAL ANTIINFLAMMATORY AGENT OR OTHER DRUG; SIDE EFFECT REDUCTION | MEDINOX, INC. | 2002-06-18 | — | — | US | disclosed |
| US-20020045573-A1 | POLYDITHIOCARBAMATE-CONTAINING NON-TARGETING MACROMOLECULES AND THE USE THEREOF FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | LAI CHING-SAN (US) | 2002-04-18 | — | — | US | disclosed |
| US-20020010208-A1 | Targeting a pharmaceutical agent to a noncentral nervous system tissue by administering a covalent conjugate of the drug and cis-docosahexanoic acid | LUITPOLD PHARMACEUTICALS, INC. | 2002-01-24 | — | — | US | disclosed |
| US-6316502-B1 | ADMINISTERING DISULFIDE DERIVATIVE OF DITHIOCARBAMATE COMPOUND TO BIND TO IRON | MEDINOX, INC. | 2001-11-13 | — | — | US | disclosed |
| EP-1151749-A1 | SHEET-FORM ADHESIVE PREPARATION | HISAMITSU PHARMACEUTICAL CO. INC. (JP) | 2001-11-07 | — | — | EP | disclosed |
| WO-2001062085-A1 | PROTECTED FORMS OF PHARMACOLOGICALLY ACTIVE AGENTS AND USES THEREFOR | MEDINOX, INC. (US) | 2001-08-30 | — | — | WO | disclosed |
| US-6274627-B1 | ADMINISTERING COMPOUNDS SUCH AS N-METHYL-D-GLUCAMINE DITHIO-CARBAMATE DISULFIDE FOR IN VIVO REDUCTION OF FREE RADICAL LEVELS IN A SUBJECT | MEDINOX, INC. | 2001-08-14 | — | — | US | disclosed |
| US-20010002404-A1 | Fatty acid-pharmaceutical agent conjugates | LUITPOLD PHARMACEUTICALS, INC. | 2001-05-31 | — | — | US | disclosed |
| EP-0866695-A4 | COMBINATIONAL THERAPEUTIC METHODS EMPLOYING NITRIC OXIDE SCAVENGERS | MEDINOX INC (US) | 2001-05-09 | — | — | EP | disclosed |
| EP-1089723-A1 | THERAPEUTIC METHODS EMPLOYING DISULFIDE DERIVATIVES OF DITHIOCARBAMATES AND COMPOSITIONS USEFUL THEREFOR | Medinox, Inc. (US) | 2001-04-11 | — | — | EP | disclosed |
| US-6190691-B1 | ADMINISTERING FORMULATION COMPRISING TUMOR NERCOSIS FACTOR (TNF) PRODUCTION-INHIBITORY AMOUNT OF A COMPOUND SELECTED FROM LOPERAMIDE AND DIPHENOXYLATE TO MAMMAL | ADOLOR CORPORATION | 2001-02-20 | — | — | US | disclosed |
| CN-1265648-A | Conjugaes of dithiocarbamates with pharmacologically active agents and uses therefor | MEDINOX INC (US) | 2000-09-06 | — | — | CN | disclosed |
| US-6093743-A | FOR IN VIVO REDUCTION OF LEVELS OF NITRIC OXIDE, SUCH AS ARE INDUCED BY A VARIETY OF DISEASE STATES, AND FOR TREATMENT OF INFECTIOUS AND/OR INFLAMMATORY CONDITIONS | MEDINOX INC. (US) | 2000-07-25 | — | — | US | disclosed |
| EP-1001932-A1 | CONJUGATES OF DITHIOCARBAMATES WITH PHARMACOLOGICALLY ACTIVE AGENTS AND USES THEREFOR | Medinox, Inc. (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999066918-A9 | THERAPEUTIC METHODS EMPLOYING DISULFIDE DERIVATIVES OF DITHIOCARBAMATES AND COMPOSITIONS USEFUL THEREFOR | MEDINOX INC (US) | 2000-03-30 | — | — | WO | disclosed |
| WO-1999066918-A1 | THERAPEUTIC METHODS EMPLOYING DISULFIDE DERIVATIVES OF DITHIOCARBAMATES AND COMPOSITIONS USEFUL THEREFOR | MEDINOX, INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| US-5962477-A | USING LOPERAMIDE | ADOLOR CORPORATION (US) | 1999-10-05 | — | — | US | disclosed |
| EP-0937460-A2 | Use of an antidiarrheal for the manufacture of a medicament for the treatment of inflammatory conditions | Adolor Corporation (US) | 1999-08-25 | — | — | EP | disclosed |
| WO-1999040787-A1 | MODIFIED PHARMACOLOGICALLY ACTIVE AGENTS AND IMPROVED THERAPEUTIC METHODS EMPLOYING SAME | MEDINOX, INC. (US) | 1999-08-19 | — | — | WO | disclosed |
| WO-1999040907-A1 | METHODS FOR THE CONTROLLED DELIVERY OF CARBON DISULFIDE FOR THE TREATMENT OF INFLAMMATORY CONDITIONS | MEDINOX, INC. (US) | 1999-08-19 | — | — | WO | disclosed |
| EP-0927159-A1 | POLYDITHIOCARBAMATE-CONTAINING MACROMOLECULES AND THE USE THEREOF FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | Medinox, Inc. (US) | 1999-07-07 | — | — | EP | disclosed |
| US-5916910-A | Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore | MEDINOX, INC. (US) | 1999-06-29 | — | — | US | disclosed |
| EP-0757558-A4 | SCREENING METHODS FOR INTEGUMENTAL INFLAMMATION MODULATING AGENTS | ALZA CORP (US) | 1999-06-16 | — | — | EP | disclosed |
| CN-1202824-A | Combinational therapeutic methods employing nitric oxide scavengers | MEDINOX INC (US) | 1998-12-23 | — | — | CN | disclosed |
| WO-1998055453-A1 | CONJUGATES OF DITHIOCARBAMATES WITH PHARMACOLOGICALLY ACTIVE AGENTS AND USES THEREFOR | MEDINOX, INC. (US) | 1998-12-10 | — | — | WO | disclosed |
| EP-0866695-A1 | COMBINATIONAL THERAPEUTIC METHODS EMPLOYING NITRIC OXIDE SCAVENGERS | Medinox, Inc. (US) | 1998-09-30 | — | — | EP | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| WO-1998011066-A1 | POLYDITHIOCARBAMATE-CONTAINING MACROMOLECULES AND THE USE THEREOF FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | MEDINOX, INC. (US) | 1998-03-19 | — | — | WO | disclosed |
| WO-1997018805-A1 | COMBINATIONAL THERAPEUTIC METHODS EMPLOYING NITRIC OXIDE SCAVENGERS | MEDINOX, INC. (US) | 1997-05-29 | — | — | WO | disclosed |
| EP-0757558-A1 | SCREENING METHODS FOR INTEGUMENTAL INFLAMMATION MODULATING AGENTS | ALZA CORPORATION (US) | 1997-02-12 | — | — | EP | disclosed |
| WO-1995027510-A1 | SCREENING METHODS FOR INTEGUMENTAL INFLAMMATION MODULATING AGENTS | ALZA CORPORATION (US) | 1995-10-19 | — | — | WO | disclosed |
| EP-0585355-B1 | MULTI-LAYERED CONTROLLED RELEASE FORMULATION | MARION LABORATORIES INC (US) | 1995-03-22 | — | — | EP | disclosed |
| US-5395628-A | Controlled release succinic acid microcapsules coated with aqueous acrylics | TANABE SEIYAKU CO., LTD. (JP) | 1995-03-07 | — | — | US | disclosed |
| EP-0581587-A2 | Base for transdermal administration | TANABE SEIYAKU CO., LTD. (JP) | 1994-02-02 | — | — | EP | disclosed |
| EP-0436370-B1 | CONTROLLED RELEASE PHARMACEUTICAL PREPARATION AND METHOD FOR PRODUCING THE SAME | TANABE SEIYAKU CO., LTD. (JP) | 1993-08-04 | — | — | EP | disclosed |
| EP-0436370-A1 | Controlled release pharmaceutical preparation and method for producing the same | TANABE SEIYAKU CO., LTD. (JP) | 1991-07-10 | — | — | EP | disclosed |
| EP-0436370-A1 | Controlled release pharmaceutical preparation and method for producing the same | TANABE SEIYAKU CO., LTD. (JP) | 1991-07-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286160-A1 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | CNR1, CNR2, GPR119 | CACNA1S 369/4885CACNA1F 900/4885ADRA1A 426/4885 |
| US-20030119796-A1 | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women | SHBG, CYP46A1, HSD3B1 | CACNA1S 3988/4885CACNA1F 3621/4885ADRA1A 618/4885 |
| US-20120264605-A1 | Multi-Functional Ionic Liquid Compositions for Overcoming Polymorphism and Imparting Improved Properties for Active Pharmaceutical, Biological, Nutritional, and Energetic Ingredients | SLC5A6, PNLIP, IPMK | CACNA1S 971/4885CACNA1F 805/4885ADRA1A 1659/4885 |
| US-20020151536-A1 | Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications | PPARG, PPARA, PPARD | CACNA1S 4536/4885CACNA1F 4442/4885ADRA1A 156/4885 |
| US-12146003-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | GUCY1A1, GUCY1A2, GUCY1B1 | CACNA1S 1275/4885CACNA1F 1605/4885ADRA1A 165/4885 |
| US-10238712-B2 | Compositions useful for the treatment of gastrointestinal disorders | GUCY1A1, TNF, GUCY1A2 | CACNA1S 3170/4885CACNA1F 3158/4885ADRA1A 412/4885 |
| US-20120077812-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | GPR119, GOT2, PC | CACNA1S 2966/4885CACNA1F 2827/4885ADRA1A 1505/4885 |
| US-20150306230-A1 | DRUG DELIVERY VEHICLES COMPRISING CELLULOSE DERIVATIVES, STARCH DERIVATIVES, AND COMBINATIONS THEREOF | PGRMC2, PGRMC1, CYP3A43 | CACNA1S 2079/4885CACNA1F 1779/4885ADRA1A 2037/4885 |
| US-20080194494-A1 | 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia | CYP46A1, CYP7A1, UGT1A1 | CACNA1S 4750/4885CACNA1F 4776/4885ADRA1A 948/4885 |
| US-20110245172-A1 | BIOCOMPATIBLE OLIGOMER-POLYMER COMPOSITIONS | BMP2, CHERP, PUF60 | CACNA1S 3820/4885CACNA1F 3624/4885ADRA1A 2993/4885 |
| US-20110021419-A1 | Methods and Compositions for the Treatment of Heart Failure and Other Disorders | GCGR, GCG, GIPR | CACNA1S 1156/4885CACNA1F 1194/4885ADRA1A 153/4885 |
| US-20080125396-A1 | Derivatives of Isothiazol-3(2H)-Thione 1,1-Dioxides as Liver X Receptor Modulators | NR1H2, NR1H3, NR1I2 | CACNA1S 4325/4885CACNA1F 4410/4885ADRA1A 310/4885 |
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | SLC5A6, PNLIP, IPMK | CACNA1S 971/4885CACNA1F 805/4885ADRA1A 1659/4885 |
| US-20030087840-A1 | Conjugates of dithiocarbamates with pharmacologically active agents and uses therefor | NOS1, PTGS1, NOS2 | CACNA1S 2573/4885CACNA1F 2341/4885ADRA1A 3053/4885 |
| US-20020192203-A1 | Sterol absorption inhibitor compositions | CYP46A1, SREBF1, FABP2 | CACNA1S 4784/4885CACNA1F 4470/4885ADRA1A 471/4885 |
| US-20070191289-A1 | Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs | SLC5A1, SLC5A2, GPR119 | CACNA1S 3069/4885CACNA1F 2970/4885ADRA1A 788/4885 |
| US-20060166899-A1 | Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof | SLC5A1, SLC5A2, SULT2A1 | CACNA1S 2783/4885CACNA1F 3158/4885ADRA1A 751/4885 |
| US-20110033465-A1 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | PCSK9, PCSK7, CETP | CACNA1S 4746/4885CACNA1F 4679/4885ADRA1A 3522/4885 |
| US-20080058306-A1 | Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitors(s) and treatments for vascular indications | PPARG, PPARA, PPARD | CACNA1S 4356/4885CACNA1F 4197/4885ADRA1A 107/4885 |
| US-20020010208-A1 | Targeting a pharmaceutical agent to a noncentral nervous system tissue by administering a covalent conjugate of the drug and cis-docosahexanoic acid | FABP7, FADS2, ALOX5 | CACNA1S 3395/4885CACNA1F 3062/4885ADRA1A 1258/4885 |
| US-20070142304-A1 | Diphenylazetidinone derivatives possessing chloesterol absorption inhibitory activity | CYP46A1, CYP51A1, NPC1L1 | CACNA1S 1832/4885CACNA1F 1666/4885ADRA1A 1750/4885 |
| US-20050080071-A1 | Treatment methods | CYP46A1, HMGCR, CYP27A1 | CACNA1S 2133/4885CACNA1F 1953/4885ADRA1A 482/4885 |
| US-20100016321-A1 | DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATOR | NR1H2, NR1H3, NR1I2 | CACNA1S 4370/4885CACNA1F 4450/4885ADRA1A 218/4885 |
| US-20140287001-A1 | Compositions Useful For The Treatment Of Gastrointestinal Disorders | GUCY1A1, TNF, GUCY1A2 | CACNA1S 3170/4885CACNA1F 3158/4885ADRA1A 412/4885 |
| US-20140155575-A1 | Process of Preparing Guanylate Cyclase C Agonists | GUCY1A1, GUCY1B1, GUCY1A2 | CACNA1S 1199/4885CACNA1F 1629/4885ADRA1A 130/4885 |
| US-20030119809-A1 | Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors | NPC1L1, NPC1, CYP46A1 | CACNA1S 4584/4885CACNA1F 3925/4885ADRA1A 2679/4885 |
| US-20050239766-A1 | Diphenylazetidinone derivatives for treating disorders of the lipid metabolism | CYP46A1, CYP27A1, CYP7A1 | CACNA1S 2731/4885CACNA1F 2702/4885ADRA1A 1401/4885 |
| US-20190262420-A1 | COMPOSITIONS USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | GUCY1A1, TNF, GUCY1A2 | CACNA1S 3170/4885CACNA1F 3158/4885ADRA1A 412/4885 |
| US-20200040038-A1 | Process of Preparing Guanylate Cyclase C Agonists | GUCY1A1, GUCY1B1, GUCY1A2 | CACNA1S 1199/4885CACNA1F 1629/4885ADRA1A 130/4885 |
| US-20090203633-A1 | PYRAZOLE DERIVATIVES, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF | UGGT1, GCKR, SLC5A1 | CACNA1S 2279/4885CACNA1F 2719/4885ADRA1A 421/4885 |
| US-20080261942-A1 | COMBINATIONS OF BILE ACID SEQUESTRANT(S) AND STEROL ABSORPTION INHIBITOR(S) AND TREATMENTS FOR VASCULAR INDICATIONS | SLC10A2, SLC10A1, CYP46A1 | CACNA1S 4540/4885CACNA1F 4484/4885ADRA1A 489/4885 |
| US-20200113968-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR DOWNREGULATION OF PRO-INFLAMMATORY CYTOKINES | GUCY1A1, GUCY1A2, GUCY1B2 | CACNA1S 3652/4885CACNA1F 3511/4885ADRA1A 305/4885 |
| US-20230340023-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | CACNA1S 1275/4885CACNA1F 1605/4885ADRA1A 165/4885 |
| US-20080207585-A1 | Substituted Azetidinone Compounds, Processes for Preparing the Same, Formulations and Uses Thereof | CYP46A1, NPC1L1, PCSK9 | CACNA1S 3646/4885CACNA1F 3506/4885ADRA1A 355/4885 |
| US-20210128511-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | ADRA2C, ADRB3, ADRA2B | CACNA1S 2706/4885CACNA1F 3552/4885ADRA1A 9/4885 |
| US-20050031651-A1 | Administering a combination of an agent that treats an amyloid-P disease, neurodegeneration, or cellular toxicity; and said second agent is a therapeutic drug or nutritive supplement | APP, IAPP, PSEN1 | CACNA1S 2526/4885CACNA1F 2970/4885ADRA1A 1610/4885 |
| US-20120040892-A9 | Methods and Compositions for the Treatment of Heart Failure and Other Disorders | GCGR, GCG, GIPR | CACNA1S 1156/4885CACNA1F 1194/4885ADRA1A 153/4885 |
| US-20230277448-A1 | CHEWABLE FORMULATIONS | SI, TAS2R39, TAS2R31 | CACNA1S 255/4885CACNA1F 191/4885ADRA1A 4146/4885 |
| US-20090005353-A1 | Non-Anilinic Derivatives of Isothiazol-3(2H)-one 1,1-Dioxides as Liver X Receptor Modulators | NR1H2, NR1H3, NR1I2 | CACNA1S 4652/4885CACNA1F 4645/4885ADRA1A 339/4885 |
| US-20090253634-A1 | Methods and Compositions for the Treatment of Gastrointestinal Disorders | GRPR, GIPR, GCGR | CACNA1S 1465/4885CACNA1F 1694/4885ADRA1A 542/4885 |
| US-20090311249-A1 | Capecitabine Combination Therapy | RICTOR, MTOR, EIF4E | CACNA1S 4601/4885CACNA1F 4252/4885ADRA1A 4643/4885 |
| US-20250152518-A1 | PEG LIPIDS AND USES THEREOF | LIPA, LIPG, LIPC | CACNA1S 4707/4885CACNA1F 4730/4885ADRA1A 4745/4885 |
| US-20060216265-A1 | Dendrimers as molecular translocators | SLC29A1, SLC29A2, TSPO | CACNA1S 3886/4885CACNA1F 3876/4885ADRA1A 606/4885 |
| US-20040138148-A1 | Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof | SLC5A2, SLC5A1, SLC2A1 | CACNA1S 1746/4885CACNA1F 2209/4885ADRA1A 1306/4885 |
| US-20120088902-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | GRPR, GCGR, GIPR | CACNA1S 1203/4885CACNA1F 1279/4885ADRA1A 687/4885 |
| US-20210403508-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | CACNA1S 1275/4885CACNA1F 1605/4885ADRA1A 165/4885 |
| US-20220031631-A1 | HIGH-PURITY PEG LIPIDS AND USES THEREOF | LIPA, HDLBP, PLTP | CACNA1S 4591/4885CACNA1F 4592/4885ADRA1A 4648/4885 |
| US-20050049203-A1 | Nitrogenous heterocyclic derivative, medicinal composition containing the same, medical use thereof, and intermediate therefor | GPR119, NPR3, SLC5A2 | CACNA1S 4005/4885CACNA1F 4050/4885ADRA1A 436/4885 |
| US-20250171497-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | CACNA1S 1275/4885CACNA1F 1605/4885ADRA1A 165/4885 |
| US-20220233471-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | CYP2C19, PAICS, CYP2B6 | CACNA1S 2040/4885CACNA1F 3768/4885ADRA1A 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.